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PREFACE
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entirely my own work.
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SUMMARY
Magnesium is the second most abundant intracellular cation 
in the human body and has an essential role in many 
biochemical and physiological processes. Magnesium 
deficiency has been implicated in the pathogenesis of 
various diseases such as diabetes mellitus, ischaemic 
cardiovascular disease and hypertension. Deficiency can 
potentiate other electrolyte abnormalities and may result 
in the development of overt neuromuscular and psychiatric 
symptoms. Symptoms may also be mild and non-specific even 
in apparently severe deficiency.
Dietary magnesium intake in the elderly tends to be lower 
than generally recommended and my own surveys indicate that 
intake amongst elderly subjects living in East Glasgow is 
even lower than reported elsewhere in the U.K. Principal 
dietary sources are from foods not rich in magnesium and 
there is little contribution from drinking water.
Although magnesium is located predominantly in bone, muscle 
and soft tissues, measurement of serum magnesium is the 
usual method of determining magnesium status in clinical 
practice. The mean serum magnesium level in elderly 
patients admitted to hospital was similar to that found in 
healthy elderly subjects living at home. However, the 
range in illness is wider and 5% of patients had a serum 
level less than 0.66 mmol/1. Severe hypomagnesaemia (serum 
magnesium less than 0.50 mmol/1) was present in 
approximately 0.5% of elderly patients admitted
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to hospital. However magnesium in serum represents less 
than 1% of body content and is considered to be an 
unreliable indicator of body status, especially in illness. 
Measurements of magnesium in peripheral blood cells were 
therefore evaluated.
Mean erythrocyte magnesium was 2.30 mmol/1 in out-patients 
and 2.35 mmol/1 in in-patients, similar to levels reported 
elsewhere. However, the distribution of in-patient values 
was quite skewed with high levels found in patients 
suffering from skin breakdown and infection. Erythrocyte 
magnesium concentration reflects body magnesium status at 
the time of erythropoiesis and can be distorted by changes 
in red cell turnover that may occur during illness. The 
raised levels found in patients with skin breakdown and 
infection almost certainly reflected a change in cell 
characteristics rather than enhanced magnesium status, thus 
reducing the value of the measurement in these and possibly 
other conditions.
Mononuclear blood cell (MBC) magnesium is considered a 
better indicator of general intracellular magnesium status. 
Two frames of reference were measured. Healthy subjects 
had a mean value of 3.5 fmol/cell, similar to other 
reports, but the same subjects had a mean value of 0.049 
umol/mg protein, lower than reported elsewhere. Values for 
in-patients were higher using fmol/cell measurements (P = 
0.028) and much lower using umol/mg protein measurements (P 
< 0.001). There was no correlation beween the two methods 
of measurement. Biological variability and analytical
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imprecision limit the use of a single MBC measurement and, 
as with erythrocytes, alterations in MBC magnesium values 
during illness could reflect altered cell characteristics 
rather than true magnesium status.
Magnesium balance is regulated by the kidneys and, except 
in renal magnesium wasting disorders, urine magnesium falls 
during deficiency. Mean values for 24 hour urine magnesium 
excretion were 2.60 mmol for healthy elderly subjects, 1.85 
mmol for normomagnesaemic in-patients and 0.96 mmol for 
hypomagnesaemic in-patients. Normal values for younger 
healthy adults are reported at 4 - 8 mmol. Accurate urine 
collections are difficult to obtain and lower excretion in 
the elderly may reflect impaired renal function rather than 
magnesium deficit.
Percentage retention of a parenterally adminstered 
magnesium load has been advocated as a reliable method for 
assessment of magnesium status in clinical practice. 
According to test criteria, all healthy elderly subjects 
studied had some degree of magnesium deficit as did most 
in-patients in whom deficit was suspected. However it is 
difficult to relate percentage magnesium retention to the 
degree of deficit. The prolonged nature of the test, the 
influence of declining renal function and difficulties with 
accurate urine collection limit the value of this procedure 
in elderly patients.
Magnesium levels in autopsy samples of skeletal and cardiac 
muscle were significantly lower in elderly patients than in 
young accident victims. No such difference was found for
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liver or kidney samples. There was close correlation 
between magnesium and potassium levels in muscle and 
heart.
A prevalence study of diuretic therapy in 570 elderly 
patients revealed a significant reduction in serum 
magnesium in those taking thiazide diuretics. In a 
subsequent prospective study of thiazide treatment in 20 
elderly hypertensive subjects, serum magnesium fell 
significantly within 2 months of starting treatment but 
remained stable thereafter; there was no change in 
erythrocyte magnesium. A separate analysis of autopsy 
samples failed to reveal a significant reduction in tissue 
magnesium in association with diuretic treatment. Diuretics 
cause mild hypomagnesaemia but evidence of clinically 
important tissue depletion is inconclusive.
No significant differences were detected in six month 
survival, duration of hospital stay or proportion of 
patients discharged home when outcome in hypomagnesaemic 
elderly patients (serum Mg < 0.65 mmol/1) and 
normomagnesaemic patients (serum Mg 0.80-0.82 mmol/1) was 
compared. Furthermore, severe hypomagnesaemia (serum Mg < 
0.50 mmol/1), although often associated with severe 
illness, was not associated with significant increase in 
six month mortality. Hypomagnesaemia was often associated 
with hypokalaemia and, in more severe cases, with 
hyponatraemia.
In a single blind study of oral magnesium supplementation 
in elderly hypomagnesaemic out-patients, effects of
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magnesium oxide (600mg daily for eight weeks) were compared 
with placebo. There was a significant rise in serum 
magnesium and serum potassium in the nineteen subjects 
(initial serum magnesium < 0.70 mmol/1) who received 
magnesium. No statistically significant changes were noted 
in other biochemical indices and supplements had no 
apparent effects on blood pressure, electrocardiogram, grip 
strength or patient wellbeing. Routine administration of 
oral magnesium treatment to asymptomatic elderly subjects 
is of dubious value but further study is required to 
evaluate the merits of such therapy during illness.
There is no single test in routine clinical use which 
unequivocally reveals magnesium deficiency. Advanced 
techniques for measurement of free ionised magnesium hold 
promise for the future but, for the time being, clinicians 
must continue to rely on simple laboratory measurements and 
clinical judgement when considering the implications of 
possible magnesium deficit in an ill elderly patient.
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PART 1
CHAPTERS 1 - 3
BACKGROUND. MAGNESIUM IN CLINICAL PRACTICE
CHAPTER 1
MY INTEREST IN MAGNESIUM
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MY INTEREST IN MAGNESIUM
1.1 Introduct1on
I have had a special interest in the magnesium status of 
elderly patients since 1980 when, as a senior house 
officer, I uncovered hypomagnesaemia in a 78 year old man 
who had presented with ataxia, tremor, and a seizure of 
uncertain aetiology. The request for a serum magnesium 
estimation was "unusual" and, having found the level to be 
low, I am told that my subsequent request for urine 
magnesium measurement was "the laboratory's first such 
request on a geriatric patient". The patient's clinical 
condition improved in association with magnesium 
supplementation and he eventually returned home.
1.2 A case of hypomagnesaemia
I have since encountered numerous cases of hypomagnesaemia 
amongst elderly patients and give the following case 
summary as an example.
An 80 year old woman was admitted to hospital on account of 
poor mobility, balance impairment, falls and general 
weakness. Her known medical history included congestive 
cardiac failure, osteoarthritis and unconfirmed alcohol 
abuse. Medications comprised frusemide 40mg daily, digoxin
0.125mg daily and potassium supplements, all taken on a 
regular long-term basis. The principal features on clinical 
examination were atrial fibrillation at a rate of 
110-120/min (ECG) and right heart failure (raised JVP,
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peripheral oedema and hepatomegaly).
Despite increasing doses of digoxin and diuretics there was 
little change in the patient's condition during the first 
week following admission. Table 1 summarises electrolyte 
results during this time.
Other results were as follows: aspartate transaminase (AsT) 
97 U/1, alanine transaminase (AIT) 45 U/1, total bilirubin 
20 umol/1, albumin 31 g/1, haemoglobin 10.9 g/dl, mean 
corpuscular volume 98 f1. Indices of thyroid function and 
results of blood glucose, vitamin B12 and folate 
estimations were within the normal laboratory range.
The patient was treated with magnesium sulphate infusion,
0.25mmol magnesium/kg, followed by a magnesium fortified 
diet. Her clinical condition gradually improved thereafter; 
she regained independence within the ward environment and 
she was able to be discharged home two weeks later. Serum 
electrolytes had almost returned to normal by the time of 
discharge.
The same patient was readmitted to hospital 5 months later 
with similar presenting symptoms of atrial fibrillation 
poorly controlled with digoxin and moderate heart failure. 
Biochemical results again indicated magnesium depletion 
(Serum Mg 0.40mmol/l, urine Mg 0.2mmol/24hrs). Alcohol 
consumption was confirmed as a contributing predisposing 
factor on this occasion.
Treatment was similar to the first admission but during 
this second occasion more emphasis was given to improved
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TABLE 1
Serum electrolytes in a hypomagnesaemic patient
Before magnesium 
treatment
After
treatment
Serum:
Day 4 Day 8 Day 21
Na" 132 132 139 mmol/1
K" 3.6 2.6 4.3 mmol/1
Cl~ 87 96 100 mmol/I
HCO3- 30 35 25 mmol/1
Urea 5.5 5.6 5.6 mmol/1
Great. 100 85 85 umol/1
Ca++(corr) 1.90 1.90 2.10 mmol/1
PO4- 1.0 0.95 0.95 mmol/1
Mg"" 0.38 0.39 0.89 mmol/1
Urine magnesium 
(mmol/24 hours)
0.9 0.7 2.8
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diet and limitation of alcohol intake on recovery. The 
patient was discharged and has since remained relatively 
well living on her own at home. A urine magnesium at follow 
up one year later was 2.7 mmol/24hrs and recent serum 
magnesium levels have been 0.76 and 0.79 mmol/1 (four years 
later).
The hypomagnesaemia noted on both admissions was probably 
multifactorial and due to diuretics, digoxin, aldosteronism 
of heart failure, and possibly alcohol and poor diet as 
contributing factors (see Chapters 2 and 3). The low urine 
magnesium excretion values were consistent with renal 
conservation (see Chapter 7).
1.3 Questions raised during clinical practice
Despite being the fourth most abundant cation in the human 
body magnesium tends not to be measured routinely on serum 
electolyte requests. Yet, in clinical geriatric practice, 
as my interest in magnesium has developed and I have sought 
serum magnesium estimations more often in ill patients, I 
have regularly encountered mild hypomagnesaemia. I have 
also uncovered encountered cases of more profound 
hypomagnesaemia both in severely ill patients and in those 
who were not so ill. With each case I have become ever 
more curious and I have come to ask myself a number of 
questions about magnesium in old age:
1. How common is hypomagnesaemia in the elderly and what 
are the predisposing factors?
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2. To what extent does serum magnesium reflect whole body 
magnesium status in health and illness?
3. In clinical geriatric practice, how useful and reliable 
are other methods for determination of body magnesium 
status?
4. Does hypomagnesaemia contribute significantly to 
morbidity and does it influence the clinical outcome?
5. Would treatment of hypomagnesaemia benefit affected 
elderly subjects?
The following chapters describe my attempts to satisfy my 
own curiosity and, in doing so, to answer these questions.
Chapter 2 is a brief review of magnesium metabolism, the 
causes, symptoms and signs of magnesium deficiency, the 
significance of such deficiency in ischaemic heart disease 
and the emerging therapeutic role for magnesium in 
myocardial ischaemia.
Chapter 3 considers the uncertainty about dietary magnesium 
requirements and, within this context, the evidence, 
including some of my own, pointing to suboptimal dietary 
intake in the elderly.
Chapters 4 to 8 consider the assessment of magnesium status 
in the elderly in clinical practice. My own studies of 
magnesium measurements in serum, erythrocytes, mononuclear 
blood cells, and urine as well as experience of the 
magnesium load procedure are outlined. The advantages and 
drawbacks of each technique are discussed and, where
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applicable, the literature pertaining to the elderly is 
reviewed.
Chapter 9 describes my study of magnesium levels in autopsy 
tissue from elderly subjects and compares results with 
those obtained from younger subjects.
Chapter 10 considers the evidence for diuretic-induced 
magnesium deficiency and describes my own cross-sectional 
and longitudinal studies in the elderly.
Chapter 11 describes my study observing the influence of 
hypomagnesaemia on the outcome of illness in elderly 
patients.
Chapter 12 describes my attempt to examine the clinical and 
biochemical effects of giving oral magnesium supplements to 
elderly subjects with mild hypomagnesaemia.
Chapter 13 summarises my observations and suggests some 
areas worthy of further research.
The literature contains several units of measurement for 
magnesium in the various body tissues: for uniformity all 
values in this text are expressed in S.I. units (1 millimol 
= 2 milliequivalents = 24.3 milligrams).
The following abbreviations have been used:
Cl = confidence interval 
sd = standard deviation
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CHAPTER 2
THE METABOLISM AND CLINICAL IMPORTANCE OF MAGNESIUM
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THE METABOLISM AND CLINICAL IMPORTANCE OF MAGNESIUM
2.1 Summary of biochemical and physiological roles
Magnesium is essential for plant and animal life. 
Chlorophyll, the green pigment of plants, could not be 
synthesized without magnesium. In the human body it is the 
second most abundant intracellular cation and fourth most 
abundant cation overall. The biochemical and physiological 
importance of magnesium has been reviewed in detail 
elsewhere [1,2,3,4]. It is essential in reactions 
involving adenosine triphosphate and it is responsible for 
catalysing approximately 300 separate enzyme systems within 
the body. Its role is that of a co-factor in biochemical 
reactions involved in cellular energy production and 
storage, protein synthesis, DNA synthesis, maintenance of 
cellular electrolyte composition, and glucose metabolism. 
The physiological properties of magnesium include control 
of neuronal activity, neuromuscular transmission, 
myocardial and vascular smooth muscle contractility, and 
skeletal muscle contraction. It has a role in temperature 
regulation, normal growth, wound healing, coagulation, 
thrombogenesis and in immunocompetence.
2.2 Distribution in the human body
The adult body content of magnesium is between 820 and 1150 
mmols (20 and 28 grams). About 60% of the total is in 
bone, 20% is located in skeletal muscle, and the remaining 
20% is distributed fairly evenly to other organs including
page 34
the kidney, liver, pancreas, and heart. Less than 1% is 
extracellular and approximately one third of the 
extracellular magnesium is protein bound (Figure 1).
Within bone there are two distinct pools of magnesium 
[5,6]. The crystal mineral lattice portion is fairly stable 
and release of magnesium from this portion is dependent on 
bone absorption and formation. It is not influenced by 
acute changes in serum magnesium. In contrast the surface 
pool is rapidly exchangeable and is the body's main 
reservoir for endogenous magnesium. The surface pool is 
difficult to evaluate clinically, but it is thought to be 
about 30% of total bone magnesium and appears to correlate 
well with plasma magnesium concentrations [7].
2.3 Magnesium absorption
The dietary intake of magnesium varies considerably but is 
generally between 8 and 12 mmol per day, lower than the 
dietary intake recommended by some (see Chapter 3). Most 
absorption of magnesium occurs in the mid-ileum [8]. 
Absorption appears to be influenced by the amount of 
magnesium in the diet, the smaller the load the greater the 
percentage of absorption [9]. Drastic dietary reduction is 
needed to induce negative balance because of extremely 
effective renal conservation and increasing proportional 
intestinal absorption with reduced dietary intake. 
Efficiency of absorption increases from about 25% of 
ingested magnesium on high magnesium diets to about 75% on 
magnesium restricted diets [10]. The exact mechanism of 
magnesium absorption is uncertain but there appears to be a
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mixture of carrier mediated transport and simple diffusion 
[11]. The recognition of familial hypomagnesaemia is 
evidence for a specific magnesium transport mechanism 
[12,13]. Growth hormone and parathyroid hormone increase 
absorption [14] and phytates and cellular phosphate reduce 
absorption. The evidence linking Vitamin D to magnesium 
absorption is conflicting [15,16,17] Calcium appears to 
influence magnesium absorption perhaps by sharing a common 
transport pathway across the intestinal wall, although the 
evidence is more convincing in animals than in man. A high 
calcium intake appears to reduce intestinal absorption of 
magnesium and also increases renal loss [18]. There is 
little or no absorption of magnesium from the large bowel. 
There is an obligatory loss of approximately 1 mmol/day 
from intestinal secretions.
2.4 Renal Handling and Magnesium Excretion
The kidney acts as the main regulator of serum 
concentration and body magnesium content. It is only the 
non-protein bound circulating magnesium that is filtered. 
Once filtered 20 - 30% is reabsorbed in the proximal tubule 
and a further 50 - 60% is reabsorbed at the level of the 
thick ascending loop of Henle. A further 1 - 5 % is 
reabsorbed at the distal convoluted tubule. These latter 
two steps appear to be under the influence of parathyroid 
hormone [19,20]. On average 3 - 8% of the filtered load is 
excreted in the urine. The renal tubule maximum capacity 
for reabsorption (T max) of magnesium occurs at serum 
levels around 0.9 mmol/1 at the upper end of the normal
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range. Hypermagnesaemia is therefore difficult to sustain 
in the presence of normal renal function. Urine magnesium 
reflects the amount of magnesium absorbed from the 
gastrointestinal tract and is therefore closely related to 
dietary intake under normal circumstances [21]. 
Reabsorption increases greatly in response to deficiency 
[22]. Increased urine calcium competitively inhibits renal 
tubular reabsorption of magnesium in the ascending 
loop of Henle [23,24]. Hypomagnesaemia can occur with 
hypercalcaemia of any cause. Hyperaldosteronism, by 
inducing sodium retention and modest extracellular fluid 
volume expansion, causes reduced reabsorption of magnesium 
in the proximal tubule and loop of Henle [25].
2.5 Magnesium lost through perspiration
Magnesium lost through perspiration is usually negligible 
in temperate climates at around 0.6 mmol/day, but can be 
higher during work in high temperature environments 
[18,26] .
2.6 Clinical manifestatons of magnesium deficiency
Until the development of atomic absorption 
spectrophotometry (AAS) in the mid-1960's, techniques for 
measurement of magnesium in body tissues and fluids were 
technically complex and unreliable and, as a result, 
relatively little attention was paid to the role of 
magnesium in clinical medicine. The availability of AAS 
provided a simple accurate and reliable method for the
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routine measurement of magnesium in small amounts of serum, 
urine and tissues [27,28]. As measurement techniques 
became more widely available much was learned about 
magnesium metabolism and its relevance to clinical 
medicine. In the early 1980s several reviews were 
published describing the clinical importance of 
hypomagnesaemia and magnesium deficiency [29,30,31,32].
The signs and symptoms of magnesium deficiency in humans 
have been well described by ShiIs who produced experimental 
magnesium deficiency in humans by severe dietary 
restriction (< 0.4 mmol/ kg/day) [22]. His principal 
biochemical findings were hypocalcaemia and hypokalaemia 
which occurred in 6 of 7 subjects despite normal intakes of 
both calcium and potassium. Clinical symptoms of anorexia 
and apathy preceded neurological signs such as the 
Trousseau sign and tremors which occurred between 25 and 
110 days. Electrocardiographic changes such as prolonged QT 
intervals were observed in 4 of 7 subjects and 
electromyographic abnormalities were observed in all 5 
subjects monitored. None of the 7 had positive 
electroencephalographic changes. Magnesium depletion was 
associated with negative potassium balance and positive 
sodium and calcium balances. All of the abnormalities 
reverted to normal with magnesium replacement. Shils was 
unable to identify any specific symptoms associated with 
magnesium deficiency per se. All of the clinical 
manifestations were consistent with hypokalaemia or 
hypocalcaemia which had occurred secondary to magnesium 
deficiency.
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Flink [29] has classified the clinical manifestations of 
magnesium deficiency into four categories viz; 
neuromuscular hyperactivity, psychiatric disturbances, 
cardiac effects, and potassium and calcium effects 
(Table 2).
2.7 Causes of magnesium deficiency
The causes of magnesium deficiency are numerous. Table 3, 
adapted from Flink [29], lists the most commonly found 
causes. Chernow et al [31] list a few additional causes 
which might be encountered in the critical care setting 
e.g. burns, hypothermia, and severe sepsis. Juan [30] lists 
causes of hypomagnesaemia rather than causes of magnesium 
deficiency. The two are not synonymous as hypomagnesaemia 
can be due to intracellular shift of the ion during stress.
Loss of magnesium from skeletal muscle during 
protein-calorie malnutrition exceeds the loss expected from 
a simple reduction in protein content and hence the 
magnesium/nitrogen ratio is reduced. During recovery whole 
body retention of magnesium is greater than that of 
nitrogen [33].
Malabsorption and increased intestinal loss are major 
causes of magnesium deficiency. Hypomagnesaemia can occur 
in various intestinal mucosal diseases and may also 
complicate pancreatic insufficiency [34]. The mechanisms 
leading to magnesium deficiency include reduced mucosal 
surface area, increased intestinal secretion of magnesium 
and the formation of insoluble magnesium soaps.
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TABLE 2
Clinical manifestations of magnesium deficiency 
(adapted from Flink [29])
A. Neuromuscular hyperactivity
1. Tremor of extremities and tongue and grimace of 
facial muscles
2. Myoclonic jerks
3. Convulsions
4. Chvostek sign (commonly)
5. Trousseau sign (rarely)
6. Spontaneous carpopedal spasm - classical tetany
(rarely)
7. Ataxia
8. Nystagmus - both lateral and vertical
9. Dysphagia and gut hypomotility
B. Pyschiatric Disturbances
1. Apathy
2. Some or all facets of delirium
3. Coma
C . Calcium and potassium effects
1. Refractory hypocalcaemia responsive only to 
magnesium therapy
2. Refractory hypokalaemia with metabolic alkalosis 
completely responsive only to magnesium therapy
D. Effects on myocardium
1. Ventricular arrhythmias - premature ventricular 
contractions and ventricular tachycardia
2. Ventricular fibrillation
3. Sudden death
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TABLE 3
Causes of magnesium deficiency in adults 
(adapted from Flink [29])
A. Nutritional Causes
1. Prolonged parenteral fluid administration, 
including "total parenteral nutrition" without 
magnesium
2. Starvation with attendant metabolic acidosis
3. Protein calorie malnutrition and kwashiorkor
4. Alcoholism
B. Intestinal Causes
1. Chronic diarrhoea from any cause
2. Intestinal malabsorption disorders
C . Renal Causes
1. Disease related
a. Renal tubular acidosis
b. Diuretic phase of acute tubular necrosis
c. Chronic glomerulonephritis and pyelonephritis
d. Familial and sporadic renal magnesium loss
2. Drug-related renal losses
a. Diuretics - loop and thiazide
b. Antibiotic-induced tubular dysfunction - 
gentamicin, ticarcillin, carbenicillin, 
amphotericin B
c. Antineoplastic drugs - cisplatin particularly, 
but also combinations of gentamicin, 
carbenicillin and a cytotoxic agent
D. Endocrine and Metabolic Causes
1. Primary and secondary aldosteronism
2. Hyperthyroidism
3. Excessive lactation
4. Pregnancy in last trimester
5. Hypercalcaemia due to malignant diseases
6. Primary hyperparathyroidism
7. Diabetic ketoacidosis
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Magnesium deficiency secondary to renal magnesium wasting 
states can be subdivided into those caused by intrinsic 
tubular disorders and those produced by extrarenal factors. 
In congenital renal magnesium wasting there is a selective 
defect in renal magnesium reabsorption leading to 
hypomagnesaemia. There may be associated loss of calcium 
and potassium with metabolic alkalosis [35]
Drug induced renal losses are often accompanied by renal 
potassium loss and hypokalaemia. Digoxin [36] and alcohol 
[37,38] can increase urine magnesium excretion. Chronic 
alcoholism is a common cause of magnesium deficiency, being 
associated with reduced dietary intake, malabsorption 
secondary to renal and pancreatic disease, increased 
intestinal loss because of vomiting and diarrhoea, and 
increased renal excretion.
About 7% of patients presenting with severe diabetic 
ketoacidosis have hypomagnesaemia. Insulin deficiency 
leads to release of magnesium from cells and excretion in 
the urine. Excretion is enhanced by the acidosis and the 
osmotic diuresis induced by glucose. Ironically insulin 
treatment drives magnesium into cells and can temporarily 
worsen hypomagnesaemia [39].
2.8 Magnesium deficiency and the cardiovascular system
Recent reviews have focussed on the links between magnesium 
deficiency and cardiovascular problems such as 
hypertension, digitalis toxicity, cardiac arrhythmias and 
ischaemic heart disease [40,41,42]. Higher death rates from
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ischaemic heart disease have been linked to low levels of 
magnesium in soil and drinking water [43]. Elwood [44] 
compared autopsy material from subjects who had died from 
ischaemic heart disease with subjects who had died from 
other causes and found magnesium to be 20% lower and 
calcium 10% higher in myocardial tissue of the ischaemic 
heart disease group. Transient hypomagnesaemia sometimes 
occurs during the first 24 hours following acute myocardial 
infarction due to migration of magnesium from the 
extracellular to the intracellular space. This flux is 
thought to be secondary to a fall in intracellular ionised 
magnesium caused by catecholamine induced lipolysis and the 
formation of insoluble magnesium soaps [45].
Hypomagnesaemia in patients with acute myocardial 
infarction or congestive cardiac failure increases the risk 
of ventricular arrhythmias [46].
2.9 The therapeutic role of magnesium
Observations such as these as well as extensive evidence 
from animal experiments have inspired the recent interest 
in the possible therapeutic role for magnesium in acute 
myocardial infarction. Recent randomised studies in which 
intravenous magnesium has been given to patients with 
suspected acute myocardial infarction, indicate that such 
treatment could possibly reduce mortality during the first 
few weeks by as much as 50% [47]. However, in these studies 
intravenous magnesium has been administered irrespective of 
magnesium status and doses have generally been far in 
excess of normal daily requirements. In all cases mean
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serum magnesium post-infusion has been raised above the 
normal reference range indicating a pharmacological rather 
than a physiological effect. The problem of distinguishing 
pharmacological and physiological properties of magnesium 
has been highlighted [48]. Iseri et al [49] reviewed the 
early reports of successful magnesium treatment of 
refractory arrhythmias, some related to digoxin toxicity, 
in patients considered to be magnesium deficient. It now 
seems likely that in some cases at least, success was due 
to pharmacological effects of large doses of parenteral 
magnesium rather than simply physiological correction of 
deficiency. The mode of action of magnesium in these 
clinical situations is unknown and too large a dose could 
have adverse consequences. Until now treatment has been 
empirical and further investigations are required to 
identify optimum dose regimens [50].
2.10 Magnesium in Old Age
In 1983 Seelig drew attention to the mechanisms through 
which magnesium deficiency might contribute to ill health 
in old age [51]. She highlighted the need for accurate 
methods of determining body magnesium status and the 
requirement for intervention studies in cases of suspected 
deficiency in the elderly. Subsequent chapters describe my 
attempts to meet Seelig's challenge.
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CHAPTER 3
MAGNESIUM AND DIET
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MAGNESIUM AND DIET
3.1 Availability in food
The nutritional intake of magnesium has diminished since 
the early 1900's in Western countries with a progressively 
higher intake of foods which are poor in magnesium. 
Selective fertilising practice has reduced the magnesium 
content of agricultural soil and the use of certain 
pesticides inhibits plant absorption of magnesium. However 
magnesium remains widely available in food. It is found 
most abundantly in beans, bananas, cocoa, nuts, whole grain 
products, cereals, some dark green vegetables such as 
spinach, and in shell fish [48,52] [Appendix 1].
Some dietary macronutrients such as calcium, phytates, 
inorganic phosphates, and fat can hinder magnesium 
absorption [53]. The magnesium content of the diet can be 
reduced during preparation of food, e.g some magnesium is 
lost into water when vegetables are boiled [54].
3-2 Dietary magnesium requirements
In considering dietary requirements one must try to 
distinguish between the average minimum intake necessary to 
prevent nutritional disease and the optimum intake required 
for good health. It is generally accepted that the amount 
of magnesium required to maintain the serum magnesium level 
within the normal reference range is more than is required 
to maintain magnesium balance. In circumstances of reduced 
dietary intake the serum magnesium level may fall as the
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body establishes "balance" at a new lower serum level. The 
new lower level is maintained by increased renal tubular 
reabsorption and by increased uptake from the 
gastrointestinal tract. However, the optimum daily 
requirements for magnesium remain uncertain and results of 
studies to determine the minimum intake required to 
maintain health have been conflicting.
Based on balance studies on 102 miscellaneous subjects 
Nordin concluded that 6 mmol (approximately 0.1 mmol/kg) 
magnesium daily should be sufficient to maintain serum 
magnesium levels within the normal range in the healthy 
adult, whilst the minimum requirement is likely to be in 
the order of 0.04 mmol/kg per day or less. Nordin was 
convinced that magnesium deficiency could not result from 
dietary deficiency in normal people on ordinary diets [21], 
Jones and colleagues found that less than 0.12 mmol/kg per 
day induced negative balance in healthy adults and that at 
least 0.17 mmol/kg per day is needed to ensure positive 
balance. However, obese subjects managed positive balance 
on 0.08 mmol/kg per day [55].
On the other hand Seelig carried out extensive reviews to 
present evidence of a dietary requirement of at least 0.21 
mmol/kg per day in health. She has pointed out that most 
of the metabolic balance data are derived from studies of 
young adults on controlled dietary intakes and do not 
reflect altered needs during growth and illness. Since 
magnesium plays an important role in protein and nucleic 
acid synthesis, Seelig has recommended safe dietary levels
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of 0.25 mmol/kg per day for women and 0.29 - 0.42 mg/kg per 
day for men [53,56].
She also believes that the elderly have higher dietary 
requirements and this view is shared by others. Intakes of 
up to 30 mmol magnesium per day have been suggested for the 
elderly [57,58].
3.3 United Kingdom recommended dietary allowance for 
magnesium
Until recently there was no specific United Kingdom 
recommended dietary allowance (RDA) for magnesium and 
investigators usually referred to the United States Food 
and Nutrition Board RDA of 12.5 - 14.5 mmol per day (0.21 
mmol/kg) [59]. However, the recent report of the Panel on 
Dietary Reference Values has produced a dietary 
recommendation for the UK which is more conservative [60] 
and reflects the calculated national average daily intake 
of magnesium amongst adults [61,62]. The report estimates 
the average daily dietary requirement to be 10.3 mmol for 
adult men and 8.2 mmol for adult women with lower safety 
limits of 7.8 mmol and 6.2 mmol respectively. Expressed in 
terms of body weight, the average daily requirement is 
estimated to be 0.14 mmol/kg per day for all adults, 
including the elderly.
3.4 Dietary magnesium intake of the elderly
A 1977/78 Nationwide Food Consumption survey in the U.S.A. 
revealed that 75% elderly men had magnesium intakes below
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the RDA of 14.5 mmol and almost 1 in 6 elderly women 
consumed less than 6 mmol (RDA for women 12.5 mmol) [63]. A 
more recent survey of 270 free living elderly (less than 
75 years) in Adelaide, Australia, revealed 42% of males and 
36% of females had a magnesium intake below the Australian 
RDA (13.5 mmol for men and 11.25 mmol for women) [64].
3.5 Dietary magnesium intake of the elderly in Glasgow
A survey of 264 elderly subjects living at home in north 
Glasgow between 1969 and 1972 revealed a wide scatter of 
dietary magnesium intake with an average daily intake of
13.5 mmol in 77 men and 9.5 mmol in 187 women [65].
However two more recent studies from elsewhere in the UK 
suggest that the Glasgow study may have overestimated 
magnesium intake in the elderly [66,67].
In view of this discrepancy and as part of a study to 
assess the effects of diuretic therapy on magnesium status 
at the time of hospital admission [68], I asked my 
colleague Karen Milligan (senior hospital dietitian) to 
estimate and compare the daily dietary magnesium intakes of 
50 frail elderly subjects and 50 younger subjects in 
relatively good health living in east Glasgow.
a) Subject selection and method of estimation
The elderly subjects were selected from hospital 
in-patients within one week of their admission to Lightburn 
Hospital. Patients were selected for interview only if 
deemed able to give a reliable dietary history. The
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assessments were of home diet prior to hospital admission 
and were based on patient recall, each patient being 
interviewed on two or three occasions to determine normal 
food habits. When possible, corroborative information was 
obtained from carers.
The 50 younger subjects, selected at random from patients 
attending a hospital contact dermatitis clinic, were 
interviewed on one occasion only and magnesium intake was 
based on 24 hour dietary recall.
For both groups the magnesium content of various foodstuffs 
was derived using standard food tables [69].
b) Results
The findings of the two surveys are summarised in Table 4. 
In 14% of elderly patients magnesium intake was estimated 
to be less than 4.11 mmol (100 mg) per day. Expressed in 
relation to body weight the average intakes were 0.11 
mmol/kg per day (sd 0.04) for both men and women. Expressed 
similarly, the daily intakes of the younger subjects were 
0.11 mmol/kg (sd 0.05) for females and 0.12 mmol/kg (sd 
0.06) for males. The younger subjects therefore had higher 
total daily intakes than elderly subjects but intakes were 
broadly similar when expressed in terms of body weight.
c) Comment
The calculated dietary magnesium intake is lower than found 
elsewhere but, as the surveys were retrospective and relied 
on recall without direct analysis of food consumed, the 
consumption of both groups may have been underestimated.
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TABLE 4
Estimated dietary magnesium intake in east Glasgow
Subjects Number 
and sex
Mean age 
(years)
Estimated intake 
mmol/day 
mean (sd)
Elderly 
(recent 
hospital 
admissions)
13 male 
37 female
79
81
6.8 (2.4) 
6.0 (2 .0)
Younger adults 
(out-patient 
attenders)
19 male
31 female
51
42
8.5 (3.0)
7.6 (3.2)
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The results of the other surveys of magnesium intake of 
elderly subjects in the United Kingdom [65,66,67] are 
summarised in Table 5. The most accurate study to date is 
that carried out by Bunker and Lawson who used duplicate 
biochemical analysis techniques [67]. The housebound 
subjects described in their study and those in hospital and 
at home in Belfast (66) had an intake approximately 25% 
greater than the estimated intake in our east Glasgow 
survey. Duplicate biochemical analysis techniques provide 
an accurate record of intake whereas even the best dietary 
record/history can only be an approximation. However 
weighing of actual diet components as in the Belfast study 
provides a more accurate record than history alone.
Although the magnesium intake of the subjects in our 
survey was perhaps underestimated there is other evidence 
to support low intake. The serum magnesium levels of 0.87 
mmol/1 for healthy elderly subjects and 0.86 mmol/1 for 
housebound subjects described by Bunker and Lawson [67] are 
higher than those of elderly living in Glasgow who have 
mean values of 0.81 mmol/1 (see Chapter 4). Similarly the 
urine excretion values of 2.6 mmol/day (housebound) and 3.2 
mmol/day (healthy) reported by Bunker and Lawson are also 
slightly higher than found in the elderly population of 
east Glasgow (see Chapter 7).
Within the United Kingdom there is considerable 
geographical variation in dietary pattern with lower 
consumption of fruit and fresh green vegetables in Scotland 
contributing to a lower magnesium intake [70]. Compared
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with the U.K. average intakes for men aged 16 - 64, men in 
Scotland have a significantly lower intake of magnesium. 
Magnesium intake of Scottish women aged 16 - 64 is also 
lower than in other regions, although the difference is 
less than in men [62]. Magnesium intake is also affected 
by socioeconomic status, being lower in low income 
families. Similar regional differences in nutrient 
consumption have previously been reported in the elderly 
population [71]. However, differences may be offset by 
relative energy consumption when magnesium intake is 
expressed as a ratio of energy intake [62]. East Glasgow 
has a high proportion of low income families and 
unemployment rates are high. The diet, especially that 
consumed by older generations, is not plentiful in 
magnesium rich food and most magnesium is derived from the 
large quantities of bread and milk consumed. Another 
factor often overlooked in dietary surveys is the 
contribution from drinking water. Glasgow water has 
relatively little magnesium, the value for east Glasgow 
being 0.02 - 0.04 mmol/1 [72]. By contrast in certain areas 
of England, borehole water has a magnesium concentration of 
approximately 2 mmol/1.
Amongst the elderly in hospital there is evidence to 
suggest that, even when the magnesium content of the 
available diet is relatively low, the effect of patient 
selection lowers still further the actual magnesium intake 
[73]. The same effect is likely to be seen in the frail 
elderly at home, many of whom are reliant on home help and 
meals-on-wheels services for meal provision.
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3.6 Summary
The recommended dietary intake for magnesium has tended to 
be higher than the actual intake of magnesium amongst 
elderly subjects. The recent United Kingdom RDA is more 
conservative than previous United States and Australian 
recommendations for magnesium intake and more accurately 
reflects actual intake in this country. However it is 
likely that elderly subjects living in east Glasgow 
continue to have a lower intake than elsewhere. Principal 
dietary sources are from foods not rich in magnesium (e.g 
bread and milk) and there is relatively little contribution 
to dietary magnesium from drinking water. Our evidence 
suggests that the elderly subjects of east Glasgow 
establish magnesium balance at lower serum levels as a 
consequence of reduced intake and this is reflected in 
lower urinary output of magnesium. Nordin has observed 
that magnesium output in urine is closely related to 
dietary intake [21].
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PART 2
CHAPTERS 4 - 9
ASSESSMENT OF MAGNESIUM STATUS IN CLINICAL GERIATRIC 
PRACTICE
CHAPTER 4
SERUM MAGNESIUM
page 57
SERUM MAGNESIUM
4.1 Introduction
Serum magnesium comprises less than 1% of the total body 
magnesium pool but, being the most readily available 
specimen, it is the usual method of determining magnesium 
status in clinical practice. Magnesium in serum exists in 
three fractions; an ultrafilterable fraction consisting of 
free ionised magnesium (60 - 62%), magnesium complexed to 
citrate, bicarbonate and phosphate (5%), and a 
protein-bound non-ultrafilterable fraction (33 - 34%) [74]. 
Approximately 25% of the total serum magnesium is bound to 
albumin and 8% to globulins. The ionised fraction is 
believed to be the physiological active fraction. Patients 
frequently have alterations in serum proteins and changes 
in acid-base status which alters protein binding, and so in 
illness serum total magnesium correlates poorly with the 
ionised fraction. Ultrafilterable magnesium comprises 
mainly the ionised fraction, and Zaloga et al [75] have 
demonstrated that serum total magnesium has 100% 
sensitivity and 73% specificity for detecting 
ultrafilterable hypomagnesaemia.
4.2 Technical Considerations
Atomic absorption spectrophotometry (AAS) is the current 
method of choice for measurement of serum magnesium. It 
has advantages over other methods in terms of precision, 
sensitivity, accuracy, and specificity [76,77]. Dye
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binding methods recover less magnesium than atomic 
absorption at low serum levels, whereas at high serum 
levels this situation is reversed. Thus reference ranges 
tend to be wider with dye binding methods of measurement.
In terms of precision, sensitivity and accuracy the titan 
yellow method is the least desirable of the dye binding 
methods [76,77].
It is important that blood is taken without undue stasis to
avoid artificial elevation of serum levels caused by a
combination of egress of cellular magnesium and raised 
serum proteins [78,79]. I have demonstrated the importance 
of separation of serum from erythrocytes as soon as 
possible after blood is drawn and certainly with four hours 
[80].
Serum magnesium has a circadian rhythm and for accuracy, 
when making intra-individual comparisons, the sample should 
be taken at the same time each day. The peak phase for
serum magnesium is late forenoon for both elderly males and
females [81].
4.3 Serum magnesium in Healthy Populations (using AAS)
The normal range for serum magnesium in healthy adults in 
the United States has been well defined by Lowenstein and 
Stanton [82]. Samples from over 15,000 persons revealed a 
mean serum level for the age range 18 - 74 years of 0.85 
mmol/1. 95% of samples fell within the range 0.75 - 0.96 
mmol/1. Levels were slightly higher for both sexes in 
infancy and childhood but fell during adult years and
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remained relatively stable thereafter.
The same authors reviewed the world literature on serum 
magnesium in healthy adult populations. They considered 18 
studies in nine difference countries in which serum 
magnesium had been measured using atomic absorption 
spectrophotometry. The mean population values for studies 
carried out in European countries (Germany, France,
Denmark, and England) ranged from 0.74 - 0.85 mmol/1. Most 
studies showed slightly higher levels for adult men 
compared with women.
4.4 Serum magnesium (by AAS) in adults living in Glasgow
The mean serum level in the healthy adult population of the
Greater Glasgow area is lower than that reported for the
United States. Seventy-one healthy volunteers, mean age
38.5 years (range 19 - 65), participating in the Good
Hearted Glasgow Project [83], were found to have a mean
serum level of 0.79 mmol/1 (sd 0.06) and range of 0.65 to
0.98 mmol/1. The samples were measured at the Department of
Clinical Chemistry, Glasgow Royal Infirmary, using atomic
absorption spectometry. The analytical error for the
*
laboratory is very small and intra-subject sampling has 
revealed a biological variation of less than 5% for samples 
taken one week apart.
* (The laboratory within-assay and between-assay standard 
deviations, for serum magnesium in the range 0.4 - 1.10 
mmol/1, are 0.005 and 0.01 respectively.)
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4.5 Serum magnesium (by AAS) in hospital and clinic 
patients
It was pointed out by Lowenstein and Stanton (82) that 
clinical ranges for serum magnesium tend to be greater as 
they include a greater percentage of abnormally low and 
high values. Mean values from clinical groups tend to be 
the same as in the healthy populations from which the 
samples are taken. Jackson and Mair [84] in 1968 suggested 
that routine serum magnesium measurement might be 
worthwhile in clinic patients after they demonstrated the 
association between hypomagnesaemia and certain clinical 
conditions. In a study of 5,100 patients they found a mean 
serum magnesium level of 0.89 mmol/1 (sd 0.08). They found 
that up to 20% of hypomagnesaemic patients had diabetes 
mellitus compared to only 3.8% with normal serum levels. 
Similarly 13% of patients on diuretic therapy were 
hypomagnesaemic compared to only 4.8% with normal serum 
levels.
Whang and colleagues [85] recommended routine measurement 
of serum magnesium with urea and electrolytes in all 
hospital patients after finding that 6.9% were 
hypomagnesaemic (less than 0.63 mmol/1) and that the 
condition was associated with alcohol related disease, 
diabetes mellitus, chronic airways disease, hypertension, 
and anaemia. The same authors [86] reiterated this 
recommendation several years later by demonstrating that 
hypomagnesaemia was associated with hypokalaemia, 
hypophosphataemia, hyponatraemia, and hypocalcaemia.
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Wong and colleagues [87] supported routine serum magnesium 
estimation after finding that 11% of hospitalised patients 
had low serum magnesium levels (< 0.6 mmol/1) and that, 
after correction for protein binding, hypocalcaemic 
patients had double the rate of hypomagnesaemia of other 
hospital patients.
4.6 Serum magnesium (by AAS) in intensive care patients
Ryzen et al [88] in a study of 94 severely ill patients in 
intensive care found that 65% of those with normal 
renal function were hypomagnesaemic (< 0.53 mmol/1) and 50% 
of patients so affected had alcohol related disease. In a 
study of 193 patients admitted to post-operative intensive 
care units Chernow et al [89] found 117 (61%) were 
hypomagnesaemic. Higher mortality and more hypokalaemia 
were found in severely hypomagnesaemic patients (< 0.5 
mmol/1) than in similarly ill patients with normal serum 
magnesium levels. Several authors have shown reduced serum 
magnesium associated with acute myocardial infarction 
[90,91].
4.7 Serum magnesium in Hospital Patients using a dye 
binding method
Reference intervals for serum magnesium have also been 
determined for hospital patients using a dye based 
colorimetric method of measurement [92]. The mean value 
for 800 patients was 0.82 mmol/1 with 95% of samples 
falling between 0.63 and 1.05 mmol/1. Exclusion of samples
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with co-existent abnormalities of calcium, albumin or 
alkaline phosphatase produced little change in reference 
intervals for serum magnesium. The mean value for the 473 
remaining patients was 0.81 mmol/1 with 95% of values 
between 0.64 and 1.03 mmol/1. These authors again found 
the serum concentration of magnesium in men to be slightly 
higher than in women and the mean value for each sex 
increased with age significantly between the third and 
ninth decades. The authors attributed this rise to 
progressive impairment of renal function.
4.8 Serum magnesium in the elderly
There have been relatively few studies of serum magnesium 
in exclusively elderly populations. Table 6 summarises the 
findings of investigators other than myself where subjects 
taking diuretic therapy have been excluded and atomic 
absorption spectrophotometry was the method of measurement 
[93,94,95,96,97]. Mean values range from 0.79 mmol/1 in 
elderly Day Hospital attenders in Ireland, to 0.89 mmol/1 
in healthy elderly women in Sweden.
In 1973 Leask et al [98] used a dye binding technique [99] 
to measure serum magnesium in 41 elderly subjects (65 and 
over) living at home either in North Glasgow or Kilsyth. 
They found a normal distribution of results with 95% 
between 0.62 and 1.02 mmol/1. The mean value overall was 
0.82 mmol/1 but was slightly higher in men (0.84 mmol/1 
compared with 0.81 mmol/1 for women).
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TABLE 6
Serum magnesium in the elderly - other investigators*
results
(Using Atomic Absorption Spectrophotometry)
Author
Country
Population
type
Number of Mean Serum mmol/I
subjects age mean (sd)
Petersen
Denmark
1977
[93]
Healthy 43 Men 
30 Women
60*
60*
0.82 (0.05) 
0.81 (0.07)
Landahl
Sweden
1980
[94]
Healthy 55 Men 
55 Women
70*
70*
0.85 (0.06) 
0.89 (0.08)
Hayes
Ireland
1989
[95]
Day
Hospital
Attenders
25 Men 77 
(M + F )
0.79 (0.09)
Sherwood
England
1986
[96]
Geriatric
Admissions
Geriatric
Admissions
17 Men 
27 Women
14 Men 
39 Women
83 
(M + F)
80 
(M + F)
0.84 (0.14)
0.80 (0.09)
Touitou
France
1987
[97]
Long Term 
Care
198 80 
(M + F)
0.83 (0.07)
all subjects
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4.9 Personal Studies of serum magnesium in the Elderly
a) Introduction
Over the years I have requested estimation of serum 
magnesium on many occasions in the course of my clinical 
practice. The estimation is now performed on my patients 
whenever magnesium depletion could be a factor in illness 
and is therefore currently measured at least once on the 
majority of my in-patient cases.
b) Blood sampling
Initial samples were taken by me as part of my research 
interest [100], but in recent years most in-patient samples 
have been taken by members of junior medical staff under my 
supervision. These staff are instructed on the problems 
posed by excessive stasis and delayed analysis of samples. 
Most samples from out-patients and all samples taken from 
healthy elderly volunteers for research purposes continue 
to be drawn by me. Except in acute illness, almost all 
samples are taken between 0800 and 1100 hours.
c) Laboratory analysis
Atomic absorption spectrophotometry has been used for all 
serum magnesium estimations. Initial samples were measured 
in the Department of Biochemistry, Victoria Infirmary, 
Glasgow [100]. Since 1985 all serum estimations have 
been performed at the department of Clinical Chemistry, 
Royal Infirmary, Glasgow. The standard deviation for
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within-assay comparisons in the latter laboratory, for 
serum magnesium in the range 0.4 - 1.10 mmol/1, is 0.005.
By agreement with the laboratory, serum not separated from 
cells by centrifugation within 4 hours of sampling time is 
not analysed for magnesium [80].
d) Results
Table 7 is a summary of serum magnesium results extracted 
from my studies of magnesium status in the elderly.
Analysis of my in-patient results reveals a slight rise in 
serum magnesium with age from 65 years upwards and the 
trend is just significant at the 5% level (Figure 2). 
Comparison of serum magnesium with serum creatinine reveals 
a significant positive relationship between the two even 
within the range of serum magnesium 0.70 - 0.92 mmol/1 
(mean + sd for the in-patient population) (Figure 3). Data 
from these studies will be presented in more detail in 
subsequent chapters.
e) General observations
Serum levels in the elderly do not differ significantly 
from those of younger adults. As is the case with younger 
adults, ranges in illness tend to be wider than those in 
health although mean values usually coincide with those of 
the healthy population. The slight rise in serum magnesium 
with age is consistent with studies of younger subjects 
which have shown a rise in serum magnesium from the age of 
20 onwards [82,92].
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TABLE 7
Serum magnesium in the elderly - Personal studies
Date
Population 
r reference]
1981
Hospital
admissions
[100]
Number of 
Subjects
107 (M+F)
(Mean)
80
Serum mmol/I 
mean (sd)
0.80 (0.11)
1987
Hospital
admissions*
[66]
1988
Outpatients
(Unpublished)
1988 
Healthy 
elderly 
at home **
(unpublished)
250 (M+F)
41 M 
105 F
11 M 
27 F
81
74
78
71
75
0.82 (0.10)
0.78 (0.08)
0.76 (0.08)
0.81 (0.06)
0.81 (0.06)
1991
Hospital
admissions
[101]
1576 (M+F) 81.5 0.81 (median)
* None taking diuretic treatment
** Attenders at a lunch and dance club
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FIGURE 2 Relationship between serum magnesium and age in 
in elderly subjects admitted to hospital
n = 670 
R = 0.07 
P = 0.05
1. 25.
ia
. 75 _ ♦ +
I
I
U)
+ +
. 25 _
1009080706050
SUBJECT AGE Cyaars)
110
page 68
FIGURE 3 Relationship between magnesium and creatinine in 
serum in elderly subjects admitted to hospital 
(serum magnesium range 0.70 - 0.92 mmol/1)
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4.10 Drawbacks of serum magnesium as an indicator of body 
magnesium status
Although easily measured serum magnesium represents less 
than 1% of total body stores. It is the ionised (free) 
portion which is important but most clinical data are based 
on measurement of total serum magnesium. The ionised 
portion, which is affected by protein binding and 
acid-base status, is difficult to measure. Alkalosis 
increases protein binding whereas acidosis decreases it 
[102]. Cellular depletion can exist with normal serum 
levels and hypomagnesaemia per se does not mean unequivocal 
magnesium depletion. During total starvation serum levels 
may be maintained despite tissue depletion because of 
catabolic release of intracellular magnesium [33]. Serum 
levels may be lowered during the stress of severe illness 
especially if there is significant pain [103]. This is 
likely to be related to adrenalin release which lowers 
serum magnesium by causing a shift into cells [104,105]. 
Adrenocorticotrophic hormone and insulin have a similar 
effect [39,106]. Many of the cases of hypomagnesaemia 
reported in medical and surgical intensive care may not 
have had tissue magnesium depletion. When such cases were 
followed up serum magnesium returned to normal within a 
short time [107].
The clinical significance of hypomagnesaemia in severe 
illness is uncertain. Many patients remain asymptomatic 
whilst others seem to be at risk of serious neurological 
and cardiological complications. Routine measurement of
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serum magnesium continues to be recommended [108] but 
difficulty with measurement of the free ionised component 
restricts our knowledge of the significance of magnesium 
changes in illness. One approach might be to measure 
ultrafilterable magnesium more often [102].
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CHAPTER 5
ERYTHROCYTE MAGNESIUM
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ERYTHROCYTE MAGNESIUM
5 -1 Introduction
Erythrocyte magnesium has been advocated as one of the two 
basic measurements of magnesium status in clinical pratice, 
the other being serum magnesium, and a mean value of 2.30 
mmol/l (sd 0.24) for erythrocyte magnesium in healthy 
adults has been derived from several population studies 
[109]. The measurement has been used in a variety of 
clinical situations on the basis that it provides a 
reasonably good and simple guide to body stores 
[90,110,111,112,113,].
5-2 Erythrocyte magnesium in elderly patients
This study was performed to compare erythrocyte magnesium 
levels in elderly out-patient attenders with levels in ill 
elderly patients on hospital admission and to assess the 
effects of illness, if any, on erythrocyte magnesium 
measurement.
a) Subjects
Serum and erythrocytes were assayed for magnesium in 150 
consecutive out-patient attenders, mean age 77 years (sd 
6.2), and in 100 in-patients, mean age 80 years (sd 7.4), 
during the first week of hospital admission. Each patient 
was allocated to one or more of 25 diagnostic subgroups 
based on known history, presenting clinical features and 
current medications.
page 73
b) Blood sampling and laboratory analysis
All samples were obtained between 0900 and 1100 hours.
Blood was drawn into 4ml potassium EDTA glass bottles 
without undue stasis. The whole blood samples were mixed 
on a rotary mixer and an aliquot taken and diluted 1 + 8 0  
with lanthanum chloride. Samples were then spun at 2,500 
rpm for 5 minutes using a Mistral 2000 centrifuge; serum 
samples were obtained and likewise diluted 1 + 8 0  with 0.5% 
lanthanum chloride. The magnesium content of both sample 
types was measured by flame atomic absorption using a 
Perkin Elmer 3030 atomic absorption spectrophotometer. The 
erythrocyte magnesium concentration was calculated by 
subtraction of the serum value from the value for whole 
blood magnesium with correction for the haematocrit:
R = S + (100 [W - S] / H) 
where R = erythrocyte magnesium, S = serum magnesium,
W = whole blood magnesium and H = haematocrit (%).
The precision of both whole blood and serum assays was 
better than 2%. Intrasubject temporal variation for 
erythrocyte magnesium was assessed by performing 2 
measurements 8 weeks apart on 16 healthy subjects. There 
was little change with time, the coefficient of variation 
being 4.2%.
c) Statistical methods
Kruskal-Wallis non-parametric test for independent groups 
and one way analysis of variance were used to compare 
erythrocyte magnesium levels of the diagnostic subgroups.
page 74
d) Results.
(i) Comparison with other studies
Table 8 shows the erythrocyte magnesium results for the 
in-patient and out-patient study groups. The findings are 
compared with the results of three previous studies of 
erythrocyte magnesium in elderly subjects also summarised 
within the table. In-patient values appear to be higher 
but differences were not significant for either sex. In 
fact the values for in-patients were considerably skewed 
with the median value being 2.28 mmol/1, 95% Cl 1.76 - 3.24 
(skew 0.82). Out-patient results on the other hand 
followed a near normal distribution, median value 2.32 
(skew 0.16).
Serum magnesium levels were normally distributed and mean 
values were similar for both in-patients and out-patients, 
0.79 mmol/1 (sd 0.08) and 0.77 mmol/1 (sd 0.07) 
respectively, with no significant sex difference within 
either group. There was a significant correlation between 
erythrocyte and serum values for out-patient samples, R = 
0.29; P < 0.001, but not for for in-patients, R = 0.14.
(ii) Effects of illness
There were no significant differences between out-patient 
diagnostic subgroups. However, amongst in-patients, those 
with infections had slightly higher erythrocyte magnesium 
levels and the subgroup admitted with infected pressure 
sores had much higher values. Table 9 shows the values for 
the 6 largest in-patient diagnostic subgroups listed
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TABLE 8
Erythrocyte magnesium in elderly subjects
Authors Subjects Number Age 
(years) 
mean (sd)
Eryth. mg. 
mmol/1 
mean (sd)
Personal Geriatric 46 male 75 (5.6)
study out-patients
104 female 79 (6.0)
2.33 (0.32) 
2.29 (0.29)
Personal Geriatric 35 male 78 (6.5)
study hospital
admissions 65 female 81 (7.8)
2.35 (0.38)
2.35 (0.38)
Sherwood Geriatric
et al. 
[96]
hospital
admissions
104 81 (6.4)
(31 male)
2.48 (0.34)
Touitou 
et al. 
[97]
Geriatric
long-term
care
90 male
291 female
80 (9.5)
2.30 (0.30) 
2.32 (0.30)
Petersen Healthy 43 male
et al. at home *
[93] 30 female
60 (all)
1.95 (0.18) 
2.03 (0.21)
* no diuretics or magnesium containing medications
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TABLE 9
Erythrocyte magnesium; In-patient diagnostic groupings
Diagnosis number erythrocyte magnesium mmol/I
mean (sd) 95% confidence interval
Alcohol related 8
disease
Degenerative 11
joint disease
Congestive 10
cardiac failure
Cerebrovascular 20
disease
Respiratory 10 *
infection
Pressure sore(s) 9 **
1.98 (0.15) 
2.24 (0.23) 
2.28 (0.23) 
2.32 (0.34) 
2.59 (0.48) 
2.85 (0.47)
1.85 - 2.11
2.04 - 2.44
2.11 - 2.45
2.16 - 2.48
2.19 - 3.00
2.48 - 3.21
* significant at 0.05 level
** chi square =22.6, P = 0.0009
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according to rank. Despite having elevated erythrocyte 
magnesium levels, the nine patients admitted with pressure 
sores had a mean serum magnesium level of 0.78 mmol/1 (sd 
0.08), marginally lower than the in-patient group as a 
whole. Five of these patients made a complete recovery and 
had repeat erythrocyte magnesium measurements. Values fell 
in all five from a mean of 3.06 (mmol/1 (sd 0.28) to 2.38 
mmol/1 (sd 0.48) over an average interval of six weeks. 
Retrospective analysis of available haematological data on 
patients with infections and/or pressure sores did not 
reveal any relationships between raised erythrocyte 
magnesium and other indices such as haemoglobin, mean 
corpuscular volume, leucocyte count or platelet count.
5.3 Further study of erythrocyte magnesium in patients 
with pressure sores
In view of the above results suggesting an association 
between skin breakdown and infection and elevation of 
erythrocyte magnesium the following additional study was 
performed.
a) Patients and methods
During a six month period patients admitted to hospital 
with pressure sores were identified. Serum and erythrocyte 
magnesium, full blood count and reticulocyte count were 
measured in the standard manner but the blood films from 
each patient were selected for special study by a trained
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haematologist. When possible the laboratory measurements 
were repeated after an interval of 8 weeks irrespective of 
skin condition.
b) Results
Of the patients identified during the study period, repeat 
samples at eight weeks were obtained in six of them.
Results are shown in Table 10. All six patients had an 
elevated erythrocyte magnesium in at least one sample, 
usually associated with a moderately high reticulocyte 
count (normal laboratory range = 30 - 100 x 10®/1). There 
was considerable variation in erythrocyte magnesium level 
between samples. Serum magnesium levels were low or normal 
in five patients and varied little between samples. No 
other abnormalities which could explain elevated 
erythrocyte magnesium were noted on examination of the 
blood films.
5.4 Discussion
The erythrocyte is not a typical cell. It has no nucleus 
and no mitochondria and the magnesium content is low 
compared with other cells. Most erythrocyte magnesium is 
in the haemoglobin. Magnesium enters the cells at 
erythropoeisis and tends to leak out exponentially as the 
cell ages [114,115]. The half period for red cell magnesium 
has been estimated at 22.4 days [116]. There is virtually 
no "exchange" of magnesium between plasma and red cells and 
the amount of magnesium in erythrocytes is largely a 
function of two variables; the age of the cells and the
page 79
TABLE 10
Erythrocyte magnesium and haematological indices in six 
patients with pressure sores; two measurements taken 8 
weeks apart
Sample Erythrocyte Serum Mean Reticulocyte
magnesium magnesium corpuscular count
mmol/1 mmol/1 volume x 10®/1
fl
1 3.38 0.80 101 115
2 2.38 0.82 95 79
1 3.46 0.81 84 132
2 2.00 0.70 81 49
1 2.69 0.91 88 82
2 3.20 0.83 104 144
1 2.76 0.66 87 108
2 2.67 0.74 87 118
1 2.60 1.08 92 68
2 3.11 1.04 98 137
1 2.37 0.87 85 121
2 3.20 0.84 87 91
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amount of magnesium in bone at the time of erythropoiesis. 
Changes in red cell magnesium occur relatively slowly and 
tend to be more moderate than those seen in serum. However 
in situations of accelerated red cell turnover a raised 
erythrocyte magnesium can occur but this does not 
necessarily imply a whole body excess of magnesium. More 
likely, it is an indication of relative youth of cells
[117].
There are two recognised methods of erythrocyte magnesium 
measurement and both methods yield comparable results
[118]. The indirect method used in this study derived the 
erythrocyte magnesium concentration from serum and whole 
blood measurements. The direct method involves measurement 
of magnesium in separated saline washed erythrocytes. 
Washing does not cause significant loss of cellular 
magnesium but it is important that a representative sample 
of cells is studied. Reticulocytes and young erythrocytes 
tend to remain at the top of a centrifuged column of red 
cells and older cells settle to the bottom [119].
Therefore either the entire column should be studied or 
only samples at the lowest level should be analysed.
Seelig, in a review of 20 studies comparing both methods, 
found a wide range of mean values (1.9 - 3.1 mmol/1) with 
an even wider "normal" ranges in some individual studies. 
Numerous sources of technical error were documented and 
doubt was cast on the reliability of erythrocyte magnesium 
as a guide to magnesium status [118].
It has been pointed out that the wide reference range for
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erythrocyte magnesium limits the value of a single 
measurement in an individual because the result obtained 
may be very unusual for the individual yet still be within 
the normal reference range [120]. There is evidence that 
erythrocyte magnesium levels are genetically determined and 
that they may be low or high in some subjects irrespective 
of magnesium status [121].
Several authors have commented on the lack of correlation 
between serum and erythrocyte magnesium levels 
[109,122,123]. In this study there was a relationship for 
magnesium between serum and erythrocytes in the relatively 
stable outpatient population. The lack of correlation 
between the two measurements in in-patients was almost 
entirely due to the high values values obtained in patients 
with infection and/or skin breakdown. These high values 
fell towards the group mean in association with healing. It 
would appear therefore that such conditions can distort 
values for erythrocyte magnesium in the same way as has 
been observed in high red cell turnover states such as 
thalassaemia and sickle cell disease [114,117]. The 
evidence suggests that increased marrow production of young 
erythrocytes can cause the high erythrocyte magnesium 
values found in most patients with skin breakdown and this 
would probably also explain the moderately raised levels 
observed in some patients with infection. More detailed 
studies of erythrocyte production and survival in these 
circumstances would be required to confirm this.
Touitou et al [97] have previously investigated the effects
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of different illnesses on erythrocyte magnesium in 
geriatric patients in long term care. Hypertension was 
associated with lowered erythrocyte magnesium levels but no 
illness category was associated with elevated levels. 
However, infection does not seem to have been considered as 
a separate diagnostic grouping.
In this study alcohol related disease accounted for the 
lowest erythrocyte magnesium levels amongst in-patients but 
differences did not reach significance at the 5% level. 
There were 18 non-insulin dependent diabetic outpatient 
attenders whose erythrocyte magnesium levels were no 
different from the group as a whole. Similarly erythrocyte 
magnesium levels in 28 hypertensive out-patients taking 
thiazide diuretic therapy were not significantly different. 
The effect of diuretic therapy on erythrocyte magnesium in 
elderly out-patients was investigated in more detail as 
described in Chapter 10.
In summary, erythrocyte magnesium levels found in these two 
groups of elderly patients are similar to those reported 
elsewhere. However the presence of skin breakdown and/or 
infection was associated with higher levels than normal in 
some cases. Such high levels are likely to be due to 
alterations in characteristics of the erythrocytes 
themselves with a higher proportion of younger cells rather 
than an indication of body magnesium excess.
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CHAPTER 6
MONONUCLEAR BLOOD CELL MAGNESIUM
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MONONUCLEAR BLOOD CELL MAGNESIUM
6.1 Introduction
Determination of magnesium in mononuclear blood cells [MBC] 
has been used as an indicator of magnesium status. There 
is some evidence of correlation for magnesium between MBC 
and muscle in human subjects and agreement is evolving for 
reference intervals using several units of measurment 
[122,124,125,126,127]. Some workers have used MBC 
magnesium to evaluate magnesium status in specific clinical 
conditions [112,128,129]. MBC magnesium has been suggested 
as a possible candidate to fulfil the requirement of a 
simple reproducible test which could be widely used to give 
meaningful information on overall intracellular magnesium 
status [130].
6.2 MBC magnesium in the elderly
It seemed appropriate to evaluate MBC magnesium measurement 
in the elderly, and the following study was performed to 
compare two frames of reference for MBC magnesium in both 
health and illness.
a) Subjects
Blood samples were obtained from 24 healthy elderly 
subjects living at home in the community and from 21 ill 
elderly subjects from the same community, but recently 
admitted to hospital with a variety of medical problems.
The community subjects comprised 9 males and 15 females,
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average age 76 years (range 67 - 93), and those in hospital 
comprised 7 males and 14 females with an average age of 79 
years (range 65 - 90).
b) Blood sampling and laboratory analysis
Blood samples were taken between 0900 and 1000 hours 
without undue stasis and measurements of magnesium in serum 
and MBCs were made as follows:
After dilution of the serum sample 1 + 7 0  with lanthanum 
chloride (0.5%) the magnesium content was determined by 
flame atomic absorption spectrometry [28]. The procedure 
for separation of cells was based on Boyum's methods 
[131,132]. Pellets of MBC were obtained, after a minimum 
period of storage of no more than four hours, by layering 8 
ml of heparinized blood on to 12 ml of Ficoll-Paque (1.077 
g/ml). The density gradient was centrifuged at 300g for 40 
minutes and the MBC layer which forms at the Ficoll - serum 
boundary was collected and washed twice with phosphate 
buffer saline (PBS) to avoid platelet contamination. The 
pellet was re-suspended in 1.5 ml of PBS and 50 ul taken 
for cell counting using a Neubauer haemocytometer. The 
cells were re-pelleted (300g, 10 minutes) and lysed with 
1.5 ml of sodium dodecyl sulphate (SDS). The magnesium 
concentration was determined on 1 ml of the lysate diluted 
1 + 1  with lanthanum chloride solution (0.5%) and analysed 
by atomic absorption spectrometry. The remaining 0.5 ml of 
the lysate was assayed for protein using the Lowry method 
[133].
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c) Precision of laboratory assays
Duplicate analysis of the samples from the 24 community 
subjects revealed coefficients of variation for MBC 
magnesium measurements to be 8.8% expressed as fmol/cell 
and 12% expressed as umol/mg protein. The equivalent 
analytical errors for magnesium, protein and cell count 
were less than 2%, 3.4% and 5 - 10% respectively.
d) Results
The characteristics of the in-patient group and the results 
obtained from them are shown in Table 11. Excessive alcohol 
consumption was a factor in two patients and 10 patients 
were receiving either loop or thiazide diuretic therapy.
No patients were receiving theophylline derivitive 
medications.
Table 12 compares results obtained for inpatients with 
those of community subjects. Inpatient MBC magnesium 
levels, expressed umol/mg protein, were significantly lower 
than those for community subjects (P < 0.001, Student’s t 
test: t = 4.59). The difference between the means of the 
two groups was 0.014 umol/mg protein, 95% confidence 
interval 0.008 to 0.02. However, expressed as fmol/cell, 
in-patients had higher MBC magnesium levels (P = 0.028).
There was no significant correlation between the two 
methods of MBC magnesium measurement for either patient 
population (Figure 4). Neither form of MBC measurement 
showed a correlation with serum values.
page 87
004J
G
O
-H
-PId
m
T5
r-H
W
I i 
I—I
M
C
e
G-H
m
Œ
Gen
■d
%
U
§
TJ
Ged
e
G
P
(Sto
1—i
I i
M
a
g
g
m en ri
O -P 03 B ri
P B P G P
O O O G
en JG
O k g G
P i
P
en
B
(D ü ü tn Q) G P
P B O B G Pi P:
G < •O Pi P o
m -P g g Pm (D O B en P* m en Q p m (D P G en r im p G ri >1 ri en r-H #—1 < 0 B GG f-H O 4G B ri G p O B P
O o 00 P G O O m P TJ 00 B en“*■4 p B O g en g P u B G P ri
P ri g m n P i g B en ü O f—( H O S-l P >
B w -r4 >1 G Q *P en ü D P H-l r i P
t 3 G P p a CD B rH #—4 ri 03 B P B
G O ri B B ri G en O JG P ü ri g G ri O
O g G ri r—i r—4 Pi ;G ü B P G B O o
Ü G B P G G 00 G O o P P O 03 ri g (9 r i
O en g ü U p 0 ü G O P i g P P G &i P gB o G G g B -v-4 m ri en pCi B 03 o O (S P: G 03 ü en O
ri o Pi < o P p u -v-4 G o < K N Pi k O G ü O G
U k P p 1—{ g **-4 O Q) B Pi
B <0 m D Q) p Pi u
TJ Q H Q > > ri p H Eli P H H k G p Pi M p
m W > K H B G ri M > ü > > > O ü H rrj O > ri
% M ü B % p Q < Pi % ü O Pi O O ü < S H ü O O
+J
O
P
A
en
gco 
o  
G 
en o
% G
§ ::3-P (D 
en u 
CD \  
G rP
en o  
ri g  % "p
en
s
g
G
P
m
en
X
m
en
en
Pri
O o  
en >1 
<  ^
GJ I I B  I Gl I I B I B B I I iP B I iP PI I I
B CN CN en CD B en
co co KO If co CN CN CN
o o o O O O O o
o o o o O O O o
B m o
O O o
co CN 00 B 00
'f Tf CO co
o o o o o
o o o o o
m o rn
o o
B  rH enB CN CNO O O
O O O O O
m  en B  eo B  m
■cj* B  m  m  U3
ri’ c N i n n t n ' ^ r ^ r o n c N
i n m e n c n n i n i n c N r o v o
en m en m B 
rn m 'd'
v£) en o ro m 
i> eo en en ■^n-^cnr^enocor^enc o o o e u v o r ^ c o c o e o c O B en co o en 00 r- en eo B
m
X
G
O
B
B
>
S
P
A
â
UB
B
(D
U P 
B  G 
•P B  
(D Q 
P
G (D 
B  TJ 
Q B  
NA ri
O B0 jG 
PI B
1 I
PI B
03
en œ
ri P
O G
en r—4
■B B
P G rio Pi
P
ri p ü
B u ri
G p B
O ri t J
en «M P
ri G ri
> M O
»—{ 1-1 en
ri ri >
P B “•H
03 XJ p
jg p en
Pi ri (D
ü en
p O G
0) >i o
Pi S o
P
G
OtG o B  m m U ri 
p  G m G H oa
en en co «f B CN B eo CN vû 'f eo co co ri"o B 00 CN o B B B
00 o in 00 00 r' 00 OO 00 eû r~ CO 00 o 00 en “B P P
ri ri
o o B o O O o O O O O o o O o B O o o o o Pi 1—1 P
pri
(D
W
ü
ri g  
p  O
P  ü  O CQ 
O H
I I I
g HI
page 88
TABLE 12
Serum and Mononuclear Blood Cell Magnesium in the Elderly
Serum
mmol/1
MBC MBC
fmol/cell umol/mg prot
Community 
subjects 
(N = 24)
0.75 (0.07) 3.5 (1.14) 0.049 (0.01)
In-patients 
(N = 21)
0.80 (0.11) 4.3 (1.20) 0.035 (0.01)
results shown as mean (sd)
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FIGURE 4 Magnesium in Mononuclear Blood Cells from
elderly hospital patients: relationship between 
measurements of fmol/cell and umol/lOOmg cell 
protein
n = 21 
R = 0.28 
NS
3 -
0 1 2 3 4 5 6 7
umol/100mg cell protein
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e) Biological variation
Biological change was assessed by drawing further samples 
from 10 community subjects later on the same day and again 
after an interval of seven days. The coefficient of 
variation for same day intrasubject analysis for fmol/cell 
measurements was 12% and at one week was 22%. The 
equivalent intrasubject values for serum were 2.8% and 4% 
respectively.
6 - 3 Discussion
The values of MBC magnesium for elderly subjects in the 
community, expressed as fmol/cell, are broadly in line with 
those found in normal controls of all ages in previous 
studies [127,134,135,136,137,138] whereas the values 
expressed as umol/mg protein are lower than in other 
studies of adults [122,128,135], but not children [136].
For both frames of reference the scatter of results is wide 
in this elderly population sample. The lack of correlation 
between the fmol/cell and umol/mg protein measurements has 
previously been observed [136] and the lack of correlation 
of either with serum has been reported by several authors.
The comparative results for ill in-patients, who had 
slightly higher values for fmol/cell and serum and much 
lower values expressed as umol/mg protein, seem at first to 
be quite bizarre. However, these conflicting results could 
reflect the effects of illness on the size and protein 
content of cells in the lysate. The magnitude of these 
illness effects on cell characteristics may
page 91
over-shadow the effects of illness on magnesium status per 
se.
With the methodology used in this study, it has been shown 
that in normal individuals MBCs account for 97% of cells 
harvested from a Ficoll-Paque gradient with more than 80% 
being lymphocytes [139]. However, changes in relative 
proportions of cells harvested as well as variations in 
cell age and size can lead to spurious results for MBC 
magnesium [140,141].
There are several different populations of circulating 
lymphocytes. They vary in size as well as function and 
have widely varying circulating life spans 
[142,143,144,145]. Larger lymphocytes tend to be those 
which have been activated by antigen and, for a fixed 
cellular concentration of magnesium, these larger cells 
will have a higher magnesium content [141,146]. Some cells 
exist for a few days whilst others survive for several 
years. Furthermore, there is evidence that the magnesium 
content of a lymphocyte gradually declines as the cell ages 
[140]. Therefore a greater proportion of larger newly 
produced cells within the lymphocyte population, as might 
be expected in response to illness, could result in a 
higher than expected value for cell magnesium content 
expressed as fmol/cell.
Monocytes usually account for less than 10% of the total 
white blood cell population and less than 20% of 
"harvested" MBC cells. However, the volume of a monocyte 
is much greater than that of a lymphocyte and, as is the
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case with larger lymphocytes, for any given concentration 
of cellular magnesium, an increase in the relative 
proportion of monocytes will result in a corresponding 
increase in the value of magnesium content/cell. An 
increased proportion of monocytes is present during the 
recovery phase of most infections, in malignant disease, 
inflammatory disorders, and in collagen-vascular diseases. 
These clinical disorders, which result in monocytosis, are 
often contributors to illness in elderly hospitalised 
patients.
Conversely these same in-patients who had slightly higher 
values expressed as cell content had low values for MBC 
magnesium expressed as umol/mg protein. A possible 
explanation for this discrepancy is that the protein 
content of cells varies greatly according to physiological 
and pathological conditions [147,148]. Protein synthesis 
is greater in cells activated during infection and 
inflammation. For a fixed amount of cellular magnesium the 
resultant increase in cell protein content will lead to an 
overall lower concentration value for magnesium when 
protein is used as the denominator. In other words the 
lower value for MBC magnesium expressed as umol/mg protein 
in these hospitalised subjects may reflect more cellular 
protein rather than less cellular magnesium.
Whilst the analytical error using these methods of 
measurement was modest and comparable with errors reported 
by others, and could account for the same day biological 
variation, there was considerable biological variability in
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measurements one week apart. It is possible that factors 
such as residual platelet contamination, despite the 
repeated washings with phosphate buffers to remove 
platelets, contributed to the analytical error.
6-4 Conclusions
There continues to be debate as to the clinical usefulness 
of MBC magnesium measurement as well as the most 
appropriate frame of reference [135,136,149]. The results 
obtained here indicate that MBC magnesium can perhaps act 
as a guide to the magnesium status of a stable population 
group and could be used to assess trends within that group 
as well as to permit comparison with other similar groups. 
However, the biologic variability and analytical 
imprecision not only preclude use of a single MBC magnesium 
measurement as an accurate guide to an individual's 
magnesium status but probably also preclude reliability of 
multiple measurements from a single individual.
Care should be taken in interpretation of values 
obtained in groups of individuals during the course of 
illness when the cell population is likely to differ from 
normal either as a result of the illness itself or even as 
a result of treatment [150]. Observed alterations in 
magnesium MBC content or concentration could reflect to a 
far greater extent the effects of illness on cell 
characteristics compared with the effects on magnesium 
status per se. Detailed analysis of the differential cell 
type and the size of cells in the lysate would be necessary
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to put magnesium values, expressed as content/cell, into 
context in each clinical situation thus adding yet another 
step to the already complicated procedure. Similarly when 
expressing the results in terms of protein the effects of 
illness and cell protein content would have to be 
considered. The technical procedures required for this 
measurement, as well as its biological variability and 
analytical imprecision would appear to limit its 
usefulness.
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CHAPTER 7
URINE MAGNESIUM
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URINE MAGNESIUM
7.1 Introduction
The kidney is the organ principally responsible for 
regulating the total body content of magnesium and 
conserves magnesium very effectively in circumstances of 
magnesium deficit [22]. Figure 5 shows how urine magnesium 
measurements can aid diagnosis in hypomagnesaemia.
7.2 Urine magnesium in the elderly
It seemed reasonable to consider the contribution of urine 
magnesium measurement to the assessment of magnesium status 
of elderly subjects. There is a circadian rhythm to the 
excretion of magnesium by the kidney and it is therefore 
preferable to collect a 24 hour urine specimen to assess 
magnesium excretion accurately [9]. Unfortunately accurate 
24 hour urine collections are not easily obtained in 
elderly subjects, especially in the geriatric ward setting, 
and a large number of collections had to be abandoned in 
the process of collecting the data presented here.
a) Subjects
Renal magnesium excretion was studied in 3 groups of 
elderly subjects. Group A comprised elderly individuals 
living at home and enjoying active retirement, most being 
recruited from local lunch and dancing clubs. The patients 
in Group B and C were recently admitted to the geriatric 
assessment ward and were undergoing medical investigations
page 97
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and/or rehabilitation. Group B patients had serum 
magnesium levels within the normal range whereas all 
patients in group C were hypomagnesaemic (serum magnesium 
less than 0.7 mmol/1). Data exclude subjects/patients 
taking diuretics, the effects of which were assessed 
separately and will be discussed in Chapter 10.
b) Methods
The purpose of the 24 hour urine collection was explained 
to each volunteer subject and an appropriate receptacle was 
provided with instructions on how to ensure accurate urine 
collection at home. In-patient urine collections were 
closely supervised by trained nursing staff who were aware 
of the purpose of the study and the need for full and 
accurate collections. A few patients had a bladder catheter 
in situ which made accurate collection more easily 
attainable. Despite precautions, many collections were 
abandoned because of contamination or being considered 
incomplete. Once complete, a 10 ml aliquot of urine was 
analysed for concentration of magnesium and creatinine and 
the 24 hour excretion of both was then calculated from the 
known total volume of the collection. The ratio of 
magnesium to creatinine excretion (Mg/Cr) was also 
calculated.
c) Results
Table 13 shows the results of complete 24 hour urine 
collections in the three groups of elderly subjects.
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Despite a wide scatter of results there was a significant 
correlation between serum magnesium and 24 hour urine 
magnesium excretion (Figure 6).
7.3 Discussion
The renal excretion of magnesium is generally reported as 4 
- 6 mmol/24 hrs for an adult taking a normal diet 
[151,152,153,154,155,156]. The results obtained here 
indicate a much lower magnesium excretion in both healthy 
and hospitalised elderly subjects. The hypomagnesaemic 
patients in Group C have an even lower urine magnesium 
excretion than the two normomagnesaemic groups and this 
would be consistent with increased compensatory renal 
conservation of magnesium in most patients within Group C. 
The values obtained are also slightly lower than those 
found in a previous study of elderly living at home (3.2 
mmol/24 hours for healthy subjects and 2.6 mmol/24 hours 
for housebound subjects), although the groups of 
individuals in that study also had higher serum magnesium 
levels than found here [67].
It is likely that several factors contribute to the 
relatively low urine magnesium values obtained for all 
three groups. Renal function deteriorates with age. The 
glomerular filtration rate (GFR) and renal plasma blood 
flow show a linear reduction with increasing age. At age 
65 there is a reduction of approximately 30% in the GFR 
compared with young adults [157]. The healthy subjects of 
Group A had a mean creatinine clearance of 61 + 25.6
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FIGURE 6 Relationship between serum magnesium and 24 hour 
urine magnesium excretion in elderly subjects 
admitted to hospital
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mls/min/1.73 . Magnesium excretion declines with GFR,
but magnesium clearance falls proportionately less than the 
GFR in renal failure indicating less reabsorption of 
magnesium per functioning nephron. This effect may be due 
to increased sodium or increased osmotic load per 
functioning nephron [158]. Reduced dietary intake (see 
Chapter 3) and reduced gastrointestinal absorption may also 
contribute to lower renal magnesium excretion in the 
elderly. For these reasons serum magnesium does not 
increase significantly in the elderly until GFR falls below 
15 mls/min.
A value for 24 hour urine magnesium considered to be very 
low in a young adult indicating renal conservation in the 
context of depleted body stores, could be normal for an 
elderly individual with renal impairment. Conversely an 
elderly subject with magnesium depletion secondary to renal 
magnesium wasting might have a urine magnesium well within 
the normal adult range. Results of urine magnesium must 
therefore be interpreted with caution and accurate 
knowledge of renal function is required. Despite declining 
renal function serum urea and creatinine are generally 
normal in the elderly individual and can be misleading. 
Normal values may reflect a state of lower protein intake 
and reduced production secondary to reduced body mass 
rather than the normal elimination of urea and creatinine.
The Mg/Cr ratio is a measure of the renal effort to 
conserve magnesium and has been suggested as an indicator 
of total body magnesium stores [159]. The low Mg/Cr ratio
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in Group C hypomagnesaemic subjects is in keeping with this 
hypothesis. It would therefore seem to be a potentially 
useful index in the elderly, compensating for declining 
renal function, since both GFR and urine magnesium tend 
to be lower in old age. The mean 24 hour urine creatinine 
in Group A subjects was 7.3 + 2.4 mmols (range 2.1 - 14.4) 
compared with a normal adult range of 9 - 18 mmols/day. 
However individual results for Mg/Cr ratio would have to be 
interpreted with caution as the ratio could be high in 
circumstances of renal magnesium wasting despite total body 
magnesium depletion.
7.4 Summary
Renal magnesium excretion is lower in the elderly 
primarily reflecting a decline in renal function. Results 
must therefore be interpreted with caution and knowledge of 
renal function is required. 24 hour magnesium/creatinine 
excretion ratio is a useful measure which helps to 
compensate for declining renal function but values are high 
in renal magnesium wasting disorders. When taken together 
with serum measurements urine magnesium can be a useful 
guide to body magnesium status but declining renal function 
can hinder accurate interpretation of results in the 
elderly.
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CHAPTER 8
THE MAGNESIUM LOAD TEST
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THE MAGNESIUM LOAD TEST
8.1 Introduction
Despite their drawbacks serum and urine magnesium 
measurements, taken together, generally give a reasonable 
indication of body magnesium status for most clinical 
situations. However, when doubt exists as to the true 
magnesium status of a patient the parenteral magnesium load 
test is currently widely reckoned to be the most clinically 
practical and reliable physiological method of assessment 
[160,161,162]. The procedure involves a 24 hour collection 
of urine for magnesium followed by an intravenous infusion 
of magnesium over several hours. A second 24 hour urine 
collection is commenced at the start of the infusion and 
the percentage excretion of infused magnesium is the 
difference between pre-load and post-load urine magnesium 
excretion divided by the infused load. Normal individuals 
in magnesium balance excrete essentially all of the 
injected magnesium within 24 hours.
This method of assessment of magnesium status has been in 
clinical use since the early 1960's [163,164,165] but there 
are still considerable variations in the accepted protocol. 
In most cases a 30 mmol magnesium load is administered over 
8 - 1 2  hours with excretion of more than 60% within 24 
hours being accepted as a normal result [160,161,166]. With 
this protocol, retention of more than 50% is considered to 
indicate depleted magnesium stores.
However, lower doses of infused magnesium, around 16 mmol,
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have been considered to be just as effective in 
discriminating between normal and depleted patients. 
Retention of more than 20% of a 16 mmol dose is considered 
by some to be abnormal [163,167,168] whilst others accept 
retention of more than 40% to be abnormal [169]. The 
duration of magnesium infusion using this dosage has not 
been uniformly defined, varying from 1 - 6  hours.
A lower dose administered over a longer period will 
minimise "renal spillage" caused by exceeding the renal 
tubular maximum for magnesium reabsorption during 
infusion. On this basis very low doses of 0.1 mmol/kg, 
given over 4 hours, have been used recently. Using this 
regimen more than 20% retention at 24 hours is highly 
suggestive of magnesium deficiency and more than 50% 
retention is considered to be diagnostic [159,170].
8.2 Experience of the magnesium load test in elderly 
in-patients with suspected magnesium depletion.
The procedure is indicated when there is doubt about 
magnesium status in circumstances where magnesium 
deficiency could exacerbate pre-existing clinical problems 
(Figure 7). It is now clear that even a low serum magnesium 
level does not necessarily imply tissue deficit in illness 
(see Chapter 4). The combination of mild hypomagnesaemia 
and low urine magnesium excretion are relatively common in 
ill elderly patients and, in these circumstances, the 
magnesium loading test would seem to be a useful means of
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both starting magnesium supplementation and, at the same 
time, identifying those patients who require longer term 
magnesium treatment.
However experience in such clinical situations has led me 
to doubt its usefulness in the elderly. A review of results 
in 23 consecutive patients, mean age 82 years, revealed 
that all but one had a positive result according to the 
test criteria. Using a modified 16 mmol load protocol 
(0.25mmol/kg body weight), 22 patients retained more than 
20% of the infused magnesium load and 19 retained more than 
50%. If the test criteria are valid, these results suggest 
a high level of magnesium deficit in this elderly patient 
population. The procedure had to be abandoned in at least 
15 patients because of incomplete urine collections.
There was a significant relationship between the level of 
serum magnesium pre infusion and the degree of magnesium 
retention as illustrated in Figure 8. However, there was a 
similar relationship between magnesium retention and 
creatinine clearance (ml/min/1.73m^):- R = - 0.59, P < 
0.01.
8.3 The magnesium load test in healthy elderly subjects
a) Aims
In view of the observations above, the following study was 
carried out with three aims.
1. To determine a reference range of results for healthy 
elderly individuals living in Glasgow to permit more
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FIGURE 8 Magnesium load test in elderly patients with 
suspected magnesium deficiency: relationship 
between pre-load serum magnesium and percentage 
magnesium load retention
(magnesium loading dose = 0.25 mmol/kg body wt.)
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enlightened interpretation of results in clinical 
practice.
2. To assess whether the decline in renal function with age 
significantly impairs the value of the procedure in elderly 
patients.
3. To compare results with other measures of magnesium 
status.
b) Subjects
It was hoped that at least 25 subjects would complete the 
study protocol. Volunteers were recruited from local lunch 
and dancing clubs for retired senior citizens. Subjects 
taking diuretic therapy and those with known significant 
medical conditions were excluded. The study received 
Hospital Ethical approval and all subjects gave informed 
consent.
c) Methods
Blood was drawn for routine electrolytes and levels of 
magnesium in serum, erythrocytes and mononuclear cells. Two 
consecutive 24 hour urine collections were performed to 
determine baseline magnesium excretion and creatinine 
clearance corrected for body surface area. Results from 
the two urine collections were averaged and the procedure 
was abandoned when there was more than a 30% variation in 
baseline magnesium excretion. Subjects with a creatinine 
clearance less than 30 ml/min/1.73m^ were excluded from 
further study. Remaining subjects were given magnesium
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sulphate by intravenous infusion in a dose of 0.25 mmol 
magnesium/kg body weight at a rate of 2.5 mmol/hour. A 
second 24 hour urine collection was commenced at the start 
of the magnesium infusion.
Magnesium retention (% ret) was calculated as follows
% ret = 100 X [1 - (post infusion urine - baseline urine)!
infused magnesium load
Blood pressure and heart rate were measured at hourly 
intervals during the infusion and for six hours thereafter. 
A standard ECG run at 50 mm/second was perfomed at the 
start and end of the magnesium infusion. Magnesium and 
other serum electrolytes were measured again at the end of 
the infusion.
d) Results
Eleven healthy subjects (5 males + 6 females), mean age 74 
years completed the protocol. One female subject, aged 76 
years, and one male subject, aged 71 years, were found to 
be hypomagnesaemic with serum magnesium levels of 0.58 
mmol/1 and 0.66 mmol/1 respectively. The mean serum 
magnesium level for the 9 normomagnesaemic subjects, 
pre-load, was 0.77 (sd 0.03) mmol/1.
The 9 normomagnesaemic subjects retained an average of 44% 
of infused magnesium. All retained more than 20% and four 
retained at least 50% of the infused dose (range 23 - 68). 
The hypomagnesaemic subjects retained 98% and 43% 
respectively (Table 14).
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There were no significant changes in blood pressure or 
heart rate during magnesium infusion. Similarly, there were 
no significant changes in serum calcium or serum potassium 
and there were no changes in PR or QT intervals on standard 
ECG run at 50 mm/second.
The data for the 9 normomagnesaemic subjects were examined 
for relationships between percentage magnesium retention 
and pre-load serum magnesium and creatinine clearance 
respectively with the following results:- 
Pre-load serum magnesium: R = - 0.33, NS 
Great, clearance ml/min/1.73m=: R = 0.39, NS
Neither mononuclear blood cell magnesium (fmol/cell) or red 
cell magnesium (mmol/1), measured prior to magnesium 
loading, showed any relationship with percentage magnesium 
retention.
e) Comment
Depending on the criteria chosen to interpret results from 
the 16 mmol magnesium load test possibly all of these 
apparently healthy elderly subjects or as few as six of 
them could be classified as magnesium depleted. Although 
not quite statistically significant at 5%, the data also 
suggest that the result of the magnesium load test in an 
elderly individual could perhaps be influenced as much by 
renal function as by underlying magnesium status. A larger 
number of subjects would have helped draw more firm 
conclusions from statistical analysis but recruitment of 
suitable volunteers proved to be difficult.
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8.4 Discussion
Cohen and Kitzes have recently performed magnesium load 
tests on 20 apparently healthy elderly men aged between 70 
and 80 years. Using criteria based on a 1 mmol magnesium 
load they categorised 7 subjects as having definite 
magnesium deficiency and a further 10 as probably deficient 
in magnesium. However they did not consider the effect of 
age related decline in renal function [171].
It has been shown that endogenous creatinine clearance 
corrected to a body surface area of 1.73m= falls by 
approximately 10 ml/min for each decade from age 20 years 
onwards [172,173]. It is therefore unlikely that loading 
test criteria used to interpret results in young adults 
will be equally valid in old age.
The magnesium load test has not been precisely defined and 
the procedure has recently been criticised on the basis 
that it is difficult to relate the percentage retention to 
the total body deficit of magnesium [152]. It is not clear 
from published reports that all investigators have 
accounted for baseline urine magnesium excretion; failure 
to do so could result in an error of 10 - 20% for magnesium 
retention.
8.5 Conclusion
The prolonged nature of the test, the influence of 
declining renal function, and the difficulties in obtaining 
accurate urine samples, as well as lack of correlation with
page 115
cellular indices, would appear to limit the role of the 
magnesium loading procedure in the assessment of magnesium 
status of ill elderly subjects.
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CHAPTER 9
MAGNESIUM IN MUSCLE AND OTHER TISSUES
A STUDY OF AUTOPSY TISSUE
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MAGNESIUM IN MUSCLE AND OTHER TISSUES
9.1 Introduction
Magnesium contained in skeletal muscle and soft tissues 
accounts for approximately 40% of total body stores. Low 
levels of skeletal muscle magnesium have been found in 
situations of chronic magnesium loss such as alcoholism 
[38,168], prolonged diarrhoeal illness [174], long term 
diuretic therapy [175,176], starvation [33], and diabetes 
mellitus [125]. In view of the evidence pointing to 
suboptimal dietary magnesium intake in the elderly (see 
Chapter 3) and the high number of positive magnesium 
retention tests (see Chapter 8), it seemed appropriate to 
assess whether this was reflected in the muscle tissue of 
elderly patients.
9.2. A study of magnesium in autopsy tissue from elderly 
subjects
As patient discomfort precluded analysis of tissue 
magnesium levels in a clinical setting, the opportunity was 
taken to measure levels of magnesium in samples of tissue 
from elderly patients obtained at autopsy. Furthermore, it 
was possible to compare results with those previously 
obtained in young accident victims [177].
a) Subjects
Autopsy tissue samples were taken from 33 aged subjects who 
had been admitted to the Glasgow Eastern District Geriatric
page 118
Service based at Lightburn Hospital. The study group 
comprised 14 males and 19 females with an average age of 80 
years (range 69 - 94). All subjects had been resident 
within the Eastern District of Glsgow prior to hospital 
admission.
b) Tissue sampling and analysis
The procedures adopted were identical to those described in 
the previous report [177]. Samples of kidney, liver, 
skeletal muscle and heart (25-50 grams wet wt.) were 
removed within 48 hours of death. Samples taken at the 
mortuary with stainless steel scalpels were put into 
plastic containers and frozen. Prior to analysis the 
samples were thawed, the exterior together with gross fatty 
and connective tissue trimmed off with a titanium knife and 
the sample freeze-dried. The samples (approx. 0.5 grams dry 
wt.) were digested with 5ml nitric acid in acid washed 
pyrex tubes and made up to 25 ml with deionised water. A 
sample of NIST1577a bovine liver was included with each 
batch. The values found for bovine liver were in good 
agreement with the certified values. Magnesium was measured 
by atomic absorption spectrophotometry.
c) Statistical methods
Student's t test was used to compare tissue magnesium 
levels found in these elderly subjects with those 
previously reported in young adults.
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d) Results
The principal cause(s) of death for each elderly subject 
based on clinical and post mortem findings are recorded in 
Appendix 2. The duration of illness prior to death was 
arbitrarily defined as "sudden" if less than 48 hours and 
"short" if between 48 hours and one week. Subjects who 
were clinicaly unwell for more than one week prior to death 
have been classified as having "chronic" illness.
The findings for the elderly subjects are summarised in 
Table 15 and compared with those previously reported in 
healthy accident victims [177]. The range of values for 
young and elderly are illustrated in Figure 9. Magnesium 
was found to be significantly lower in the muscle and heart 
of elderly subjects. No difference was found in kidney 
levels. For liver the group variances were different (P < 
0.001, F = 6). Some elderly subjects had much lower 
magnesium levels whereas others had higher levels. 
Expression of results per unit of nitrogen did not 
contribute additional useful information. There was no 
relationship between duration of illness and tissue 
magnesium concentrations amongst elderly subjects.
Potassium was also measured (flame photometry). It was 
found to be significantly lower in the muscle (P < 0.001: t 
= 5.2: Cl 2.8 - 6.4) and heart (P < 0.001 : t = 5.9 : Cl
2.2 - 4.6) of elderly subjects. It was also lower in the 
kidney tissue of elderly subjects (P < 0.05). No difference 
was found in liver potassium content between young and
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TABLE 15
Magnesium in autopsy tissue (mq/kq dry weight)
mean age Muscle Heart Liver Kidney 
(years)
Elderly
subjects 80 724(123) 853(128) 565(112) 655(68)
n = 33
Young
accident 29 943(143) 981(147) 578(41) 691(78)
victims 
n = 12
P<0.001 P<0.001
t = 4 . 7 t = 4 . 9
tissue values expressed as mean(sd)
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FIGURE 9 Magnesium in autopsy tissue from young accident 
victims and elderly hospital patients (ug/kg dry weight)
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elderly. When the values for young subjects and elderly 
subjects were considered as one group there was a highly 
significant correlation between concentrations of potassium 
and magnesium in both heart, R = 0.88; P <  0.001, and 
muscle, R = 0.92; P < 0.001, (Figure 10).
9.3 Discussion
A progressive fall in levels of magnesium with age has been 
noted in myocardial tissue of rats [178]. A previous study 
failed to detect any influence of age on the magnesium 
content of human autopsy tissue [179]. However in that 
study less than 1 in 10 of the study population were aged 
over 65 years at the time of death, only liver was 
examined, wet weight was used as the frame of reference, 
and all subjects were accident victims. In this study dry 
weight has been used as the frame of reference and the aged 
subjects died as a result of illnesses of varying 
complexity and duration.
It is probable that several factors such as disease, drug 
therapy, the magnesium content of diet and drinking water 
[180], as well as the ageing process itself have 
contributed to varying extent to the lower levels of 
magnesium in heart and muscle of these elderly subjects.
The observed effects of diuretics are considered in more 
detail in Chapter 10. The values for muscle magnesium 
obtained in young accident victims are similar to those 
obtained in previous studies of autopsy tissue from 
accident victims where dry weight was used as the frame of
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FIGURE 10 Relationship between magnesium and potassium in 
skeletal muscle obtained at autopsy from young 
accident victims and elderly hospital patients
n = 45 
R = 0.92 
P < 0.001
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reference [6,180]. The values are also in line with results 
obtained in biopsy samples from healthy volunteers 
[175,176].
The clinical significance of lower magnesium in muscle and 
heart of elderly subjects is uncertain. The close 
relationship between magnesium and potassium in muscle 
tissue has been observed by others [6,176,181]. Most 
investigators agree that muscle magnesium content does not 
contribute greatly to the readily exchangeable body 
magnesium pool but low levels probably reflect prolonged 
magnesium depletion. Furthermore, muscle magnesium 
depletion can lead to loss of potassium from muscle with 
eventual potassium depletion. Such potassium depletion 
proves refractory to treatment unless magnesium status is 
also corrected [181,182,183]. However, since muscle 
magnesium relates poorly to magnesium content of serum and 
bone but is so closely related to muscle potassium content, 
it has been argued that muscle magnesium depletion is 
likely to be a reflection of low body potassium stores 
rather than low magnesium stores [6].
9.4. Summary
This study of autopsy tissue has revealed significantly 
lower muscle stores of magnesium in elderly patients 
compared with younger subjects. There is no single test in 
routine clinical practice which unequivocally reveals 
magnesium deficiency and the drawbacks of the those
page 125
utilised in previous chapters have been discussed. 
Nevertheless, the cummulative evidence from dietary 
surveys, urine measurements, loading tests and autopsy 
tissue analysis tends to support a degree of magnesium 
deficit in the elderly patient population studied.
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PART 3
CHAPTER 10
DIURETICS AS A CAUSE OF MAGNESIUM DEPLETION
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DIURETICS AND MAGNESIUM IN THE ELDERLY
10.1. Introduction
Diuretics are listed among the various causes of 
hypomagnesaemia outlined in Chapter 2. This chapter 
investigates more fully the relationship between these 
commonly prescribed drugs and magnesium depletion in 
elderly subjects.
Increased urinary excretion of magnesium with diuretic 
therapy is well documented and diuretics are a recognised 
cause of magnesium depletion [184,185,186]. Diuretics are 
frequently prescribed for the elderly [187] but, in 
contrast to diuretic induced potassium losses, the 
potential problem of diuretic induced magnesium depletion 
has not been widely recognised. The relationship between 
diuretics and magnesium in the elderly has therefore been 
investigated in three studies.
10.2. Study 1: Prevalence of diuretic associated 
hypomagnesaemia in the elderly
a) Introduction
This study was designed to assess the prevalence of 
hypomagnesaemia in ill elderly patients following hospital 
admission with particular reference to the effects of 
different types of diuretic therapy.
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b) Patients and Methods
Serum total magnesium concentration was measured in 320 
consecutive elderly patients who were known to be taking 
diuretic therapy at the time of hospital admission. During 
the same period serum magnesium concentration was also 
measured in 250 consecutive patients who had not been 
receiving diuretics. All serum samples were obtained as 
part of a standard biochemistry admission profile, the 
majority being taken within 24 hours of hospital admission. 
Laboratory analysis for magnesium by atomic absorption 
spectrophotometry [28] was performed within four hours of 
venepuncture.
24 hour urine magnesium output and creatinine clearance 
were measured in selected patients who were either 
normomagnesaemic (serum magnesium 0.70 - 1.0 mmol/1) and 
not receiving diuretics, or were hypomagnesaemic. The 
hypomagnesaemic patients were divided into representative 
sub-groups receiving either thiazide diuretics, loop 
diuretics, or potassium conserving combinations, and a 
group not receiving diuretics.
Prior to initiating a 24 hour urine collection, a second 
serum sample was obtained to verify serum magnesium status. 
All patients received a standard hospital diet containing 
an average of 8 mmol magnesium daily for at least three 
days prior to the urine collection. Urine collections were 
closely supervised by trained nursing staff who recorded 
each episode of micturition. When urine incontinence was 
recorded or daytime micturition intervals exceeded 4 hours
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the urine collection was repeated or the procedure was 
abandoned. Diuretic therapy and dosage remained unchanged 
until the completion of urine collections.
Percentage renal excretion of magnesium was calculated by
the formula -
% Ex. Mg. = Urine Mg (mmol/24 hrs) x 100
Serum Mg x creatinine clearance
To compensate for the effect which varying renal function 
might have on urine magnesium excretion between groups, the 
ratio of magnesium concentration (mmol/1) to creatinine 
concentration (umol/1) was calculated on each 24 hour urine 
collection.
Most patients receiving loop diuretics and potassium 
sparing combinations were being treated for cardiac 
failure, whereas the majority of patients taking thiazide 
diuretics were hypertensive with approximately 50% having 
suffered a cerebrovascular incident. Respiratory infection 
and gastrointestinal disorders were the most common 
diagnostic categories in patients not receiving diuretics.
c) Statistical methods
One-way analysis of variance and independent t tests were 
used to compare means of normally distributed data and the 
Kruskal-Wallis test was used for comparisons of skewed 
data.
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d) Results
During the study period approximately 36% of patients were 
receiving diuretic treatment at the time of admission in 
the proportions 50% loop diuretics, 30% thiazides, 20% 
combinations which included potassium conserving agents.
The results of serum magnesium analysis on 570 patients 
comprising 320 consecutive patients receiving diuretics, 
subdivided according to class, and 250 patients, not 
receiving diuretics, are shown in Table 16.
Mean serum magnesium was significantly lower in those 
patients receiving thiazide diuretics compared with those 
not taking diuratics. Serum magnesium levels tended to be 
inversely related to the dose of bendrofluazide, the most 
commonly prescribed thiazide diuretic, but the effect was 
not statistically significant. There were no significant 
differences in serum magnesium levels among patients taking 
the various types of potassium sparing diuretics.
Twenty-four hour urine collections were obtained in 84 
patients. Urine magnesium excretion in 30 normomagnesaemic 
patients (mean serum magnesium 0.83 mmol/1 (sd 0.06)) was
1.46 mmol/24 hours (sd 0.66) with a range of 0.18 to 3.16 
mmol. The overall magnesium/creatinine excretion ratio for 
these patients was 0.35 (sd 0.28). The results of urine 
magnesium excretion for the four hypomagnesaemic sub-groups 
are shown in Table 17 and illustrated in Figures 11 and 12. 
All four groups had a wide range of urine magnesium 
excretion values with no significant differences between 
groups (Kruskal-Wallis one-way ANOVA).
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TABLE 16
Serum magnesium and diuretic therapy in elderly patients
Type of 
Diuretic
No. of 
patients
Serum mg 
mmol/1 
mean (sd) 
(95% C.I.)
% below % below 
0.70mmol/l 0.67mmol/l
Loop
Thiazide
160
94
Potassium 66
conserving
combinations
No diuretic 250
0.80 (0.12) 
(0.78-0.82)
0.77 (0.11) 
(0.75-0.79)
0.80 (0.11) 
(0.77-0.83)
0.82 (0.10) 
(0.81-0.83)
10
27
12
14
one-way ANOVA for all four groups; F = 5.07, P < 0.005
* Thiazide Vs No diuretic; P < 0.001 ; Student's t test 
99% confidence interval for the difference = 0.02 to 0.08
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FIGURE 11 Urine magnesium excretion in elderly
hypomagnesaemic.. subjects; effect of different 
classes of diuretics
(serum magnesium less than 0.7 0 mmol/1)
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FIGURE 12 Ratio of magnesium/creatinine excretion in 
24 hour urine collections from elderly 
hypomagnesaemic subjects: effect of different 
classes of diuretics
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e) Discussion
Loop diuretics have been most commonly implicated in 
magnesium depletion [112,175,188,189,190] although studies 
have often tended to be on subjects in heart failure where 
the effects of digoxin [25] and secondary aldosteronism 
[36,191] may have contributed to magnesium losses.
By exerting their main action in the ascending part of the 
loop of Henle, where most of the filtered magnesium is 
reabsorbed, it is not surprising that the loop diuretics 
are liable to produce magnesium deficiency. However, the 
increase in urine magnesium excretion induced by loop 
diuretics may be partly due to mechanisms other than direct 
blockade of magnesium reabsorption [192].
The results of this study indicate that, when compared with 
loop diuretics in ill elderly patients, thiazide diuretics 
are just as likely to be associated with hypomagnesaemia.
It has long been known that thiazide diuretics cause an 
increase in urine magnesium excretion [193]. Thiazides are 
active at the proximal part of the distal convoluted tubule 
where only about 5% of filtered magnesium is reabsorbed. 
Most magnesium loss is therefore likely to be due to an 
indirect effect of thiazide treatment. Thiazides also 
cause changes in calcium reabsorption and chronic 
administration can cause hypocalciuria, elevated serum 
calcium and a reduction in serum parathyroid hormone. This 
in turn results in reduced magnesium reabsorption at the 
loop of Henle and increased urine magnesium excretion
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[192,194]. Thiazide-induced alteration in the 
renin-angiotensin-aldosterone system may add to increased 
urine magnesium excretion [185,191].
Thiazides are commonly prescribed for treatment of 
hypertension and most studies of younger patients have 
revealed some lowering of serum magnesium associated with 
such treatment. However there is no clear consensus as to 
whether such changes are clinically significant 
[195,196,197,198].
The reported magnesium-conserving abilities of potassium 
sparing diuretics [190,199] are supported by results of 
this study. Neither serum levels nor urine magnesium 
output differed significantly from those of patients not 
receiving diuretics.
The results of this study show that whilst increased urine 
magnesium losses are induced by diuretic therapy, the wide 
range of urine excretions found in all groups studied make 
attempts to relate urine magnesium excretion to serum 
levels of limited value in the individual subject.
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10.3. Study 2: Thiazide diuretic therapy ; a prospective
analysis of serum magnesium in hypertensive patients
a) Introduction
Lowered serum magnesium levels and hypomagnesaemia in 
association with thiazide diuretic treatment in the elderly 
has been observed in studies by others following hospital 
admission [21,22] and in hypertensive patients in the 
community [201]. Like Study 1 described above these studies 
were cross sectional surveys, the exact duration of 
thiazide therapy was either unknown or approximated, doses 
varied, and factors other than thiazide therapy which could 
influence magnesium status were likely to be present 
especially in ill hospitalized patients.
The following prospective study was therefore performed to 
assess more precisely the timing and magnitude of changes 
in magnesium status in elderly patients induced by thiazide 
treatment.
b) Subjects and Methods
Elderly out-patients with untreated hypertension were 
considered for selection and 20 subjects aged between 65 
and 80 years (mean age 72 years) were recruited over a two 
year period. Prior to treatment all 8 men and 12 women had 
systolic blood pressure above 160 mm mercury and diastolic 
pressure above 90 mm mercury on three consecutive occasions 
one month apart and none of the patients had previously 
received treatment for hypertension. All subjects were
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living at home and were free from other significant medical 
disorders. All had normal biochemical and haematological 
profiles at commencement of the study. Subjects were 
prescribed bendrofluazide 5 mg daily and were reviewed at 1 
month, 2 months, 4 months, 6 months, 12 months, 18 months 
and 24 months after commencement of treatment. At each 
review biochemical indices including serum magnesium were 
checked between 0900 and 1000 hours following an overnight 
fast.
The study received hospital ethical committee permission 
and all participants gave informed consent.
c) Results
Follow up was completed in 15 patients to one year and in 
12 patients to two years. There was a significant fall in 
serum magnesium between month 0 and month 2 (P = 0.039, 
paired t test) and thereafter the serum magnesium level 
remained relatively constant (Figure 13). During the first 
2 months there was also a rise in mean serum calcium 
concentration, corrected for albumin binding, from 2.44 
mmol/1 (sd 0.09) to 2.49 mmol/1 (sd 0.08) (P = 0.009, 
paired t test). The mean serum calcium remained at between
2.47 and 2.49 mmol/1 thereafter. There was a gradual fall 
in mean serum potassium concentration from 4.32 mmol/1 (sd 
0.35) before treatment to 4.17 mmol/1 (sd 0.42) at 12 
months and it remained at this level thereafter. This 
change did not reach significance at the 5% level.
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FIGURE 13 Serum magnesium in elderly subjects receiving 
Bendrofluazide 5mg daily for treatment of 
hypertension
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Erythrocyte magnesium was measured in 14 subjects during 
this study. There was no significant change in mean 
erythrocyte magnesium concentration analysed at various 
intervals between month 0 and month 24 (Table 18).
d) Discussion.
Animal studies and some clinical studies have failed to 
show a significant change in serum magnesium as a 
consequence of short term thiazide treatment [185]. However 
most prospective studies of thiazide treatment lasting 4 
months or more have shown a significant reduction in serum 
magnesium and this has been dose related [192,196,197]. A 
study by Cocco et al [202] of younger hypertensive patients 
used serum measurements and magnesium loading tests 
performed at 0, 6 and 12 months to determine changes in 
magnesium status from commencement of thiazide treatment. 
Results of that study indicated that magnesium losses are 
already maximal at 6 months and persist thereafter. Recent 
work by Siegal et al [203] randomised 233 hypertensive men, 
average age 61 years, to 6 forms of treatment each lasting 
2 months. Subjects had received supplementation with 
magnesium and potassium for 1 month prior to randomisation 
and treatment. At 2 months there were small reductions in 
mean serum magnesium in 60 subjects given 
hydrochlorothiazide and in 30 given chlorthalidone. These 
reductions did not reach significance at the 5% level but 
in both groups the number of subjects with hypomagnesaemia 
(<0.70 mmol/1) more than doubled. The authors pointed out
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TABLE 18
Erythrocyte magnesium and bendrofluazide treatment in 
elderly subjects with hypertension
Duration of 
treatment 
(months)
Number of 
subjects
Erythrocyte Mg mmol/1 
mean (sd) 95% confidence
interval
0 14 2.29 (0.41) 2.06 - 2.53
2 14 2.30 (0.41) 2.07 - 2.56
6 14 2.37 (0.37) 2.17 - 2.56
12 12 2.26 (0.29) 2.08 - 2.45
18 12 2.17 (0.34) 1.96 - 2.39
24 12 2.24 (0.27) 2.11 - 2.37
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that prolonged treatment might result in greater reduction 
in serum magnesium especially in older subjects in whom 
additional risk factors for magnesium loss are more likely 
to be present.
The fall in serum magnesium in the elderly subjects in this 
study is more pronounced than has been observed in younger 
subjects. Lower body magnesium stores and/or altered 
homeostatic responses to thiazide-induced magnesium loss 
are possible contributing factors. The rise in serum 
calcium which also occurred within the first 2 months of 
treatment supports the evidence that thiazide-induced 
changes in serum concentrations of both elements are linked 
[192]. Serum levels of neither element changed 
significantly after 2 months. The plateau in serum 
magnesium may be due to increased intestinal absorption 
compensating for thiazide-induced renal losses with 
re-adjustment of magnesium balance at a lower serum level 
[21]. However it is possible that some magnesium is 
mobilised from body stores and, therefore, tissue magnesium 
depletion could arise over a prolonged period especially in 
circumstances of poor dietary intake or malabsorption 
co-existed.
Some previous studies have shown a reduced concentration of 
magnesium in erythrocytes in association with long-term 
thiazide treatment [112,201] whilst another failed to do so 
[167]. The erythrocyte is not a typical cell and magnesium 
concentration may not accurately reflect the situation in 
the intracellular environment elsewhere.
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Some workers have measured mononuclear cell magnesium to 
determine the intracellular effects of diuretic treatment 
[112,167,203]. Such measurements were commenced in this 
study but soon abandoned because of the excessive 
intra-subject variation evident in a control group.
10.4. Study 3; Effect of diuretics on magnesium levels in 
autopsy tissue of elderly subjects
a) Introduction
Studies have indicated risk of significant magnesium 
depletion in skeletal muscle resulting from long term 
treatment with loop diuretics [175,199] but studies of 
thiazides have produced conflicting results [167,199].
There has been little information relating to the situation 
in old age and the following analysis was therefore 
performed.
b) Methods
Magnesium concentrations in autopsy skeletal muscle and 
heart tissue from the 33 elderly subjects described in 
chapter 9 were grouped according to diuretic use prior to 
death (Appendix 2). Data from 15 subjects who had not 
received any form of diuretic therapy during the 3 months 
before death were compared with those from 14 subjects who 
had been taking one or more diuretics daily for at least 1 
year (5 loop diuretics, 5 thiazides and 4 potassium 
conserving combinations). The remaining 4 subjects did not
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fit into either category and were excluded from the 
analysis.
c) Results
There was a trend for subjects taking both loop and 
thiazide diuretics to have lower levels of magnesium in 
skeletal muscle but confidence intervals were wide and 
differences were not significant at the 5% level in either 
skeletal muscle or heart (Table 19) (Kruskal-Wallis one way 
analysis of variance). Furthermore, the mean skeletal 
muscle magnesium concentration of 682 mg/kg (sd 145) for 
the combined loop and thiazide diuretic groups was not 
significantly different from those not taking diuretics,
(P = 0.086, Mann-Whitney).
10.5 Discussion
The balance of evidence from my own studies and the 
literature points to a small but significant reduction in 
serum magnesium as a consequence of both loop and thiazide 
diuretic treatment. However intracellular losses probably 
only occur to a significant degree in a small minority of 
susceptible individuals after prolonged treatment. High 
diuretic dosage, poor dietary magnesium intake and 
co-existent disease such as heart failure, alcoholism and 
diabetes mellitus increase risk of magnesium depletion.
Do diuretic-induced magnesium losses matter? Are there 
clinical circumstances when magnesium supplements should be 
given with diuretic treatment? The rationale for magnesium
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TABLE 19
Effect of diuretics on magnesium in autopsy tissue from 
elderly subjects
Diuretic type No.
Skeletal muscle tissue
Magnesium concentration 
(mg/kg dry wt.)
mean (sd) 95% confidence 
interval
Loop diuretic 5
Thiazide 5
Potassium 4
conserving
No diuretic 15
711 (194) 
657 (80) 
732 (146)
770 (146)
469
556
498
952
957
966
713 - 826
Diuretic type No
Heart tissue
Magnesium concentration 
(mg/kg dry wt.)
mean (sd) 95% confidence 
interval
Loop diuretic 5 886 (68) 802 - 791
Thiazide 5 851 (157) 656 - 1047
Potassium
conserving
4 688 (234) 315 - 1068
No diuretic 15 895 (69) 856 - 933
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supplementation mirrors the situation with potassium since 
both elements are closely interrelated at a cellular level 
[185,186,190,204]. However after 20 years of debate there 
is still controversy as to the clinical indications or even 
need for potassium supplementation with diuretic treatment 
[205,206,207,208,209,210,211].
Hollowfield [186] has advocated use of potassium/magnesium 
conserving diuretics as first line treatment in appropriate 
patients. He cited the close cellular interrelationship 
between magnesium and potassium, the evidence of increased 
ventricular ectopic activity associated with magnesium and 
potassium depletion with the risk of sudden death, and the 
concern that tissue depletion of both elements may arise 
with normal serum levels.
Ryan [185] has followed a similar line of reasoning and, in 
addition, argued that magnesium supplementation may be 
beneficial in the treatment of hypertension.
More recently Whang et al [204] have gone further and 
recommended provision of magnesium supplements to all 
patients with low serum potassium even when the serum level 
of magnesium is unknown. However Siegal et al [203] failed 
to find any evidence that diuretic-induced magnesium loss 
resulted in increased ventricular ectopic activity after 2 
months of diuretic treatment and therefore concluded that 
routine supplementation or use of potassium/magnesium 
conserving agents is unnecessary. These investigators 
recognised that a small proportion of patients are at risk 
with diuretic treatment but also pointed out the very large
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clinical study which would be needed to accurately quantify 
the risk.
The debate continues...
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PART 4
CHAPTERS 1 1 - 1 2
ASSESSMENT OF THE CLINICAL IMPORTANCE OF HYPOMAGNESAEMIA IN 
THE ELDERLY
CHAPTER 11
THE CLINICAL SIGNIFICANCE OF HYPOMAGNESAEMIA
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THE CLINICAL SIGNIFICANCE OF HYPOMAGNESAEMIA
11.1 Introduction
Hypomagnesaemia is not an uncommon finding in ill patients 
at the time of hospital admission. It is often associated 
with other biochemical abnormalities such as hypocalcaemia, 
hypokalaemia, and hypophosphataemia, which may persist 
until the altered magnesium status is corrected 
[86,87,108,212]. In many clinical situations the true 
relevance of hypomagnesaemia can be difficult to evaluate 
and this is particularly so in the frail elderly who are 
more likely to present with complex multiple pathology.
11.2. Clinical outcome in hypomaqnesaemic elderly patients 
admitted to hospital
This study was performed to measure the prevalence of 
hypomagnesaemia and associated biochemical disturbance in 
elderly patients at the time of hospital admission and to 
compare clinical outcome in hypomagnesaemia patients with 
outcome in patients with normal serum magnesium levels. The 
prevalence of hypermagnesaemia and clinical outcome in such 
patients was also recorded.
a) Subjects and methods of determining clinical outcome
Serum magnesium estimations were performed on 1576 
consecutive patients admitted to Lightburn hospital over a
page 150
two year period beginning January, 1987. Some patients had 
more than one sample taken so that approximately 2600 
samples were taken in total for magnesium estimation during 
the study period. The first sample from each patient, 
usually taken within 24 hours of hospital admission, was 
termed the index sample and used as the baseline for 
classification and outcome measurements. Clinical outcome 
in patients with an initial serum magnesium in the lowest 5 
per cent of the observed range was compared with outcome in 
a representative cohort of patients with normal index serum 
magnesium levels. Outcome was measured in terms of duration 
of hospital stay and survival to six months from the time 
of the index sample. Those patients who were discharged 
from hospital were reviewed on an out-patient basis. In a 
small number of cases when direct patient contact could not 
be re-established following hospital discharge, information 
on survival was obtained from relatives and family 
doctors.
b) Measurement of associated biochemical disturbance
Blood sampling and magnesium analysis were performed in the 
fashion already described (see Chapter 4). As part of a 
standard biochemistry admission profile, samples were also 
analysed for levels of calcium, phosphorus, and albumin. 
Serum measurements of sodium, potassium, and creatinine, 
performed at the same time as magnesium analysis, were 
included in analysis for the second year of 
the study.
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c) Statistical methods
The Chi-square test, the independent t test and the 
Mann-Whitney U test were used where appropriate. All mean 
values are quoted with one standard deviation for Gaussian 
distributions. Median values and range are quoted for 
skewed distributions.
d) Results
(i) Population characteristics and serum magnesium levels
The mean age of the study population of 1576 patients was
81.5 years (sd 7.2). During the study period 169 patients 
(10.7 per cent) had an initial serum magnesium level less 
than 0.7 mmol/1, the lower limit of the laboratory 
reference range, and of these 70 were below 0.65 mmol/1 
(4.4 per cent of the total study population). Thirty-one 
patients (2 per cent) had a serum magnesium level greater 
than 1.0 mmol/1. The median serum magnesium for the 
population was 0.81 mmol/1 with the distribution being 
slightly skewed towards the lower end. Ninety per cent of 
values were within the range 0.66 - 0.95 mmol/1 and there 
was no sex difference for median serum magnesium, or for 
the frequency of either hypermagnesaemia or 
hypomagnesaemia. In practice all patients with an initial 
serum magnesium below 0.65 mmol/1 were classified as 
hypomagnesaemic and their outcome was compared with 100 
consecutive patients with an index serum magnesium in the 
range 0.80-0.82 mmol/1.
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(il) Outcomes
Table 20 compares the outcome for both hypomagnesaemic and 
normomagnesaemic groups and shows that there was no 
significant difference between the two groups for any of 
the outcome measurements. The 14 hypomagnesaemic patients 
who died had an initial mean serum magnesium level of 0.57 
mmol/1 (sd 0.05) compared with a mean level of 0.59 mmol/1 
(sd 0.04) in the 56 survivors (not significant).
(iii) Factors associated with hypomagnesaemia
Tables 21 and 22 illustrate the spectrum of illness and 
medications, respectively, at the time of hospital 
admission in both the hypomagnesaemic patients and in the 
cohort with normal serum magnesium levels. Diuretic therapy 
was the factor most commonly associated with 
hypomagnesaemia. Eight hypomagnesaemic patients were 
taking more than one type of diuretic. The breakdown of 
diuretic therapy in both groups of patients is shown in 
Table 23.
A serum albumin below 33 g/1 was considered to be abnormal 
[98]. Hypoalbuminaemia was noted in 24 (34 per cent) of 
hypomagnesaemic patients and in 14 per cent of the 
normomagnesaemic cohort. The mean serum albumin for each 
group was 34.3 g/1 (sd 6.7) and 38.3 g/1 (sd 5.0) 
respectively, significantly lower in the hypomagnesaemic 
patients (t = 4.13, P < 0.001). However, apart from those 
subjects with a very low serum albumin, no correlation was 
evident between albumin and magnesium for the population
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TABLE 21
Elderly patients admitted to hospital: most common diagnoses
Hypomagnesaemic patients 
(serum mg < 0.65 mmol/1) 
n = 70
Normal serum magnesium 
(serum mg 0.80-0.82 mmol/I) 
n = 100
Diagnosis Number of 
patients (%
Diagnosis Number of 
patients (%)
Ischaemic heart disease 28 (37) Cerebrovascular disease 27
Heart failure 19 (27) Ischaemic heart disease 22
Cerebrovascular disease 12 (17) Arthritis 20
Arthritis 12 (17) Heart failure 19
Infections (all types) 11 (15) Infections (all types) 12
Diabetes mellitus 11 (15) Chronic airways disease 11
Neoplastic disease 9 (13) Diabetes mellitus 10
Chronic airways disease 8 (11) Anaemia 9
Peptic ulceration 6 (9) Hypertension 8
Anaemia 6 (9) Hypothyroidism 8
Average of 2.4 diagnoses 
per patient (range 1 - 6 )
Average of 2.1 diagnoses 
per patient (range 1 - 5 )
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TABLE 22
Elderly patients admitted to hospital: most common medications
Hypomagnesaemic patients 
(serum mg < 0.65 mmol/1) 
n = 70
Medication Number
Normal serum magnesium 
(serum mg 0.80-0.82 mmol/1) 
n = 100
Medication Number
Diuretics 55
Simple analgesics 17
Digitalis 17
Bronchodilators 16
Iron supplements 7
Oral hypoglycaemics 7
Antibiotics 7
NSAIDS* 7
H2 receptor antagonists 6
Diuretics 38
Simple analgesics 33
Laxatives 19
NSAIDS* 9
Bronchodilators 8
Oral hypoglycaemics 8
Thyroxine 7
Digitalis 7
Iron supplements 7
Total medications 219
3 patients on no medication
Total medications 226
11 patients on no medication
* Non steroidal anti-inflammatory drugs
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TABLE 23
status in elderly patients on admission to hospital
Hypomagnesaemia 
(serum mg 
< 0.65 mmol/1)
Normal serum mg. 
(0.80-0.82 mmol/1)
n = 70 n = 100
Patients taking 
diuretics
47 (67%) 34
Number of diuretics 55 38
Thiazides 23 9
Loop diuretics 21 19
Potassium sparing agents 11 10
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as a whole. A low serum albumin was associated with 
increased mortality in both hypomagnesaemic patients and 
patients with normal serum magnesium : eight of 24 (33 per 
cent) hypomagnesaemic patients (X^ = 4.04; P < 0.05), and 
six of 14 (43 per cent) normomagnesaemic patients (X^ = 
5.31; P < 0.02) died within six months. Of patients with a 
serum albumin above 33 g/1, six of 48 (13 per cent) died in 
the hypomagnesaemic group compared with 14 of 86 (17 per 
cent) in the normomagnesaemic group. Assuming 30 per cent 
binding of magnesium to albumin, no case of hypomagnesaemia 
was considered to be due solely to a low serum albumin.
(iv) Associated electolyte depletion
The frequency of depletion of other electrolytes in the 70 
hypomagnesaemic patients is shown in Table 24, and can be 
compared with the population frequency of depletion of 
these same electrolytes and coincident hypomagnesaemia 
shown in Table 25. Thus 13% of hypomagnesaemic patients had 
a serum potassium below 3.0 mmol/1, whereas 56% of 
hypokalaemic patients were also hypomagnesaemic. The 
occurence of hypocalcaemia was considerably reduced when 
corrected for albumin binding (normal range for corrected 
serum calcium = 2.22 - 2.60 mmol/1).
Six month mortality rates for the nine hypokalaemic 
subjects and 16 hyponatraemic subjects, identified during 
the second year of the study, were 0 and 8 (50%) 
respectively.
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TABLE 24
Coincident electrolyte depletion in 70 hypomaqnesaemic 
elderly patients on admission to hospital
Number of 
Patients (%)
Hypokalaemia (< 3.5 mmol/1) 15 (21)
(< 3.0 mmol/1) 9 (13)
Hypocalcaemia (< 2.0 mmol/1) 9 (13)
(< 2.2 mmol/1)* 2 (3)
Hypophosphataemia (< 0.7 mmol/1) 2 (3)
Hyponatraemia (< 130 mmol/1) 1 (1)
* Corrected calcium = measured calcium + 0.02 x (47 
albumin g/1)
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TABLE 25
Frequency of electroyte depletion in 1576 elderly patients 
on admission to hospital
Number %
Coexistent
Hypomagnesaemia
(< 0.65mmol/l)
No. %
Hypomagnesaemia 
(< 0.65 mmol/1)
Hypocalcaemia*
(< 2.0 mmol/1)
Hypophosphataemia 
(< 0.7 mmol/1)
Hypokalaemia**
(< 3.0 mmol/1)
Hyponatraemia**
(< 130 mmol/1)
70
37
16
2 9 24
1 2 13
9 1 5 56
16 2 1 6
* Not corrected for protein binding 
** Study population 902
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(V ) Hypermagnesaemia
The diagnoses of the 31 patients with elevated serum 
magnesium (greater than 1.0 mmol/1) are listed in Table 26. 
Some patients had multiple problems. Within the six month 
period, fifteen (48%) of these 31 hypermagnesaemia patients 
died (X^ = 7.4: P < 0.01). All 15 patients had
biochemical evidence of chronic renal impairment (serum 
creatinine persistently above 150 umol/1), and their mean 
presenting serum magnesium was 1.11 mmol/1 (sd 0.11), 
compared with a mean of 1.06 mmol/1 (sd 0.06) for the 16 
hypermagnesaemia survivors (difference not significant).
The serum level of the hypermagnesaemia survivors generally 
returned to within the normal range, reaching a mean of 
0.92 mmol/1 (sd 0.09) at six months. In contrast the serum 
levels of those who died tended to remain high until death.
e) Discussion
The prevalence of hypomagnesaemia encountered in this study 
is similar to that found in other populations of elderly 
in-patients (see Chapter 4), and once again diuretic 
therapy, particularly with thiazides, seems to confer an 
increased risk of hypomagnesaemia (see Chapter 10). The 
rates of associated electrolyte disturbance are close to 
those previously reported with the interdependence of 
magnesium and potassium again being apparent. The 
association of hypermagnesaemia with renal impairment has 
been recognised [84], and as the latter condition is not
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TABLE 26
Diagnoses in 31 elderly hypermaqnesaemic patients on 
admission to hospital. (Serum magnesium > 1,0 mmol/1)
Diagnosis No. of patients
Chronic Renal Failure 17
Heart disease 8
Pulmonary disease 7
Respiratory infection 5
Dehydration 4
Parkinson's disease 4
Carcinomatosis 3
Other conditions 10
Contributing causes
K+ conserving diuretics 10
Magnesium supplementation 1
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uncommon in seriously ill elderly patients, the high 
mortality in patients with hypermagnesaemia and chronic 
renal failure is perhaps not surprising.
In view of the severe morbidity and risks which have been 
attributed to magnesium depletion, it is perhaps rather 
surprising that this study failed to reveal any difference 
in outcome between patients admitted with hypomagnesaemia 
and those admitted with normal serum magnesium levels. 
Furthermore, mortality in hypomagnesaemic patients was much 
lower than that in hyponatraemic and hypoalbuminaemic 
patients from the same population.
The fact that outcome for patients hypomagnesaemic on 
hospital admission was virtually the same as outcome for 
patients with normal serum magnesium levels could be due to 
several factors.
Many of the patients who presented with hypomagnesaemia in 
this study subsequently received treatment which directly 
or indirectly could have improved magnesium status; e.g. 
oral magnesium supplements (a few cases), cessation of 
diuretic therapy, improvement of diet, and control of 
diabetes mellitus. Furthermore, serum can be a misleading 
guide to true body status and, as there is evidence that 
normal serum levels can occur despite tissue depletion 
(see Chapter 4), some of the normomagnesaemic cohort may 
have been tissue depleted.
A study of patients admitted to surgical intensive care, 
many of whom were hypomagnesaemic, failed to reveal any
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correlation between serum magnesium and severity of illness 
or clinical outcome [89]. Evidence now indicates that the 
stress of acute illness can result in temporary 
hypomagnesaemia caused by a shift of magnesium from serum 
into cells. This magnesium shift is mediated by 
catecholamine release and occurs especially if pain is 
present [103,104]. In such circumstances the serum level 
generally returns to normal after a few days. However, in 
this study of elderly patients, almost half of the 
hypomagnesaemic survivors were still hypomagnesaemic on 
re-testing at six months, suggesting genuine depletion of 
magnesium, yet they did not seem to be particularly 
disadvantaged by this.
11.3. Clinical outcome in severe hypomagnesaemia
Since completion of the above study (11.2) it has been 
possible to review the clinical outcome in all cases of 
severe hypomagnesaemia encountered in elderly patients 
admitted to hospital during a six year period.
a) Methods
Patients with a serum magnesium less than 0.50mmol/l whilst 
in the Geriatric Assessment Unit at Lightburn Hospital 
during the period 1987-1992 were identified by means of a 
Department of Clinical Chemistry computer archives search. 
Data on clinical diagnoses, approximate duration of illness 
and outcome at six months were then obtained by review of 
individual case records. Six months survival data were
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checked with family medical practitioner records in 5 cases 
with incomplete hospital records.
b) Results
Serum magnesium was measured in 4,088 individual 
in-patients during the six year period and 22 patients 
(0.5%) had one or more samples less than 0.50 mmol/1. Most 
of these severely hypomagnesaemic patients were very ill; 4 
patients died within two weeks of the lowest recorded serum 
magnesium level and a total of 8 (36%) died within six 
months. Hypomagnesaemia was associated with hyponatraemia 
(serum sodium < 130 mmol/1) in 7 patients of whom 3 died, 
and 6 patients were hypokalaemic (serum potassium < 3.0 
mmol/1) of whom 1 died. Low serum magnesium levels often 
recurred or persisted for several weeks despite efforts to 
correct magnesium status in such patients using oral and/or 
parenteral supplements. Three patients were again severely 
hypomagnesaemic during a second hospital admission within 
six months, two of these being related to excessive alcohol 
intake, and all 3 survived for at least a further six 
months. Further patient details are given in Appendix 3.
Despite evidence of severe illness in most of these 22 
severely hypomagnesaemic patients, mortality rate at six 
months was not significantly greater than in the cohort of 
100 normomagnesaemic patients referred to previously in 
section 11.2. (X^ = 2.72).
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11.4 Conclusions
The common association of hypomagnesaemia with hypokalaemia 
is confirmed and more profound hypomagnesaemia in severe 
illness is also often associated with hyponatraemia.
However the relative importance of hypomagnesaemia in ill 
elderly subjects, many of whom present with multiple 
pathology, remains uncertain. An abnormally high serum 
magnesium in the presence of renal impairment appears to be 
a poor prognostic indicator in ill elderly patients.
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CHAPTER 12
EFFECTS OF MAGNESIUM SUPPLEMENTATION; A STUDY OF ELDERLY 
HYPOMAGNESAEMIC SUBJECTS GIVEN ORAL MAGNESIUM SUPPLEMENTS
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EFFECTS OF MAGNESIUM SUPPLEMENTATION; A STUDY OF ELDERLY 
HYPOMAGNESAEMIC SUBJECTS GIVEN ORAL MAGNESIUM SUPPLEMENTS
12.1. Introduction
Routine serum magnesium estimation is advised whenever 
knowledge of electrolyte levels is required and 
prophylactic low dose oral therapy is recommended in 
patients at risk of magnesium depletion [4,213]. However 
the effects of such therapy have recieved little detailed 
study and thus the evidence of benefit is sparse. Older 
subjects are already prescribed a disproportionately high 
number of medications and as many as three quarters have 
problems with compliance [214]. I was unable to find 
convincing evidence that hypomagnesaemia worsenes clinical 
outcome in in-patients (see Chapter 11), and this study was 
performed to assess whether routine treatment of the 
condition in the elderly can be justified on the basis that 
such treatment produces beneficial effects.
Constrained by the limited resources available in routine 
clinical practice, an explanatory type study [215] was 
devised based on a relatively homogeneous group of 
patients considered likely to respond to treatment.
Hospital ethical committee permission was obtained to study 
the effects of oral magnesium therapy in elderly 
hypomagnesaemic out-patients.
12.2. Patients and methods
Elderly subjects attending the out-patient department or
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day hospital and found to be hypomagnesaemic (serum 
magnesium < 0.70 mmol/1) were considered for inclusion in 
the study. Informed consent was sought from subjects with 
stable clinical conditions who were considered unlikely to 
require alterations to their existing medication regimens 
during the study period. Subjects with renal impairment, 
defined as serum urea above 10 mmol/1 and/or serum 
creatinine above 130 umol/1 were excluded from study.
12.3. Study design
Magnesium deficiency is associated with various 
biochemical, electrocardiographic, neuromuscular and 
psychiatric abnormalities (see Chapter 2). With the 
potential for many beneficial effects resulting from 
correction of magnesium deficit, it was necessary to focus 
on a few parameters whilst also monitoring the effects of 
treatment as widely as was feasible in the circumstances of 
the study. The effects of magnesium supplements on serum 
potassium were considered of primary interest (see Chapters 
9, 10 and 11).
Though desirable, it was not feasible in the circumstances 
of the study to compare the effects of magnesium 
supplementation with placebo by means of a completely 
double blind crossover design, and so the following 
compromise was used. The study was supervised by myself in 
a single blind fashion, but all clinical mesasurements were 
performed in a double blind fashion by selected members of 
clinic staff. Identical capsules containing either 300mg
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magnesium oxide (7.5 mmol magnesium) or placebo were 
supplied by the hospital pharmacy. Capsules were prescibed 
twice daily, each treatment phase lasted 8 weeks, and 
measurements were made at 4 points as follows:
1 (week 0) 2 (week 8) 3 (week 16) 4 (week 24)
Start End of placebo End of magnesium Follow up
This daily dose of 15 mmol magnesium is considered adequate 
for treatment of mild magnesium deficiency although 
considerably larger doses can be administered with safety. 
As repletion continues progressively less of the oral dose 
is absorbed from the gastrointestinal tract [216,217,218].
12.4. Biochemical measurements
Venous blood samples were taken without undue stasis 
between 0900 and lOOOh following an overnight fast. Three 
mis of each sample were immediately centrifuged to separate 
serum which was then frozen at minus 50 degees centigrade 
until analysed in batches for concentration of parathyroid 
hormone (1-84) (PTH) by two-site immunoradiometric assay 
[219]. Remaining blood was sent for standard hospital 
laboratory analysis of magnesium in serum and erythrocytes 
(atomic absorption spectrophotometry), other routine serum 
electrolytes (SMAC II autoanalyser), glucose (hexokinase 
method, Hitachi 747), glycosylated haemoglobin A1 (Corning 
electrophoresis), concentrations of triglyceride and total 
cholesterol (Hitachi 704 enzymatic process, Boheringer 
Mannheim) and HDL (manganese precipitation method).
In addition 24 hour urine magnesium excretion was measured
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before and after magnesium supplementation in 9 subjects 
recruited to the study.
12.5. Other measurements
The following measurements were made late morning, 11 am - 
noon, with the subjects relaxed following a light snack.
1) Supine and erect blood pressure were measured by a 
trained nurse (the same individual for most of the study), 
using a standard mercury sphygmomanometer.
2) Hand grip strength was measured by the same trained 
nurse using an adjustable hand dynamometer (Jamar model 
lA, Asimow Engineering Company), recording the highest of 3 
measurements for each hand.
3) A standard electrocardiogram was recorded at 50
mm/second for measurement of heart rate and rhythm, PR and
QT intervals. ECG recordings were performed by the clinic
technician, coded and randomised, and analysed all together
at the end of the study by an independent analyst. QT
intervals were corrected for rate using Bazett's formula
viz; QTc = measured QT interval(seconds)
^y^receding RR interval
4) Morale and psychological wellbeing were assessed using 
3 quick and simple self-rating scales.
a) A scaled down (12 item) version of the General Health 
Questionaire (GHQ) [220] (Appendix 4) was used to assess 
symptoms of depression and anxiety. A bimodal response 
scale was used to interpret the GHQ score with "less" or 
"no more" than usual, scoring zero and "rather" or "much
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more" scoring one. This method gets around the problem of 
"end-users" or "middle users", that is those subjects who 
always respond at the extremes of scales or always use the 
middle options. A similar method was used to record 
responses to the "faces" scale (see below).
b) The Wakefield Self Assessment Depression Inventory [221] 
(Appendix 5), also a 12 item questionaire, was used as a 
further measure of depressive symptoms.
These two self assessment questionaires were both designed 
for non medically sick individuals and have been widely 
used. They have been validated and are considered reliable 
[222,223,224].
c) The "faces" scale (Appendix 6) has been developed by the 
Department of Behavioural Sciences, University of Glasgow, 
to assess morale in elderly patients in various clinical 
settings. Experience at Lightburn Day Hospital has 
indicated that it is liked and easily understood by elderly 
subjects who have problems reading or understanding more 
commonly used visual analogue scales and quality of life 
questionaires. A bimodal response scale was again used with 
faces A and B scoring -1, C scoring 0, and D and E scoring 
+1.
All 3 questionaires were administered by the trained nurse 
who provided guidance or assistance when required.
12.6. Statistical analysis
For each variable, results at all 4 measurement points were 
compared using one way analysis of variance for normally
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distributed data and Friedman's test for non-parametric 
data. Significant differences were further examined by 
applying the paired t test and the Wilcoxon test 
respectively to compare data between two measurement 
points. Because they were of primary interest changes in 
serum potassium were taken at face value but, to compensate 
for the effect of multiple comparisons, changes in other 
parameters were adjusted by means of the Bonferroni 
correction [215].
12.7. Results
Twenty-five subjects entered the study and twenty-two 
subjects, nineteen female, mean age 81 years (sd 6.6), 
commenced the magnesium supplementation phase. Capsule 
counts indicated fairly good medication compliance among 
participants but two misunderstood instructions and took 
only one capsule daily and a third stopped treatment after 
4 weeks, having misplaced the remainder of her supply. Data 
from these three subjects have been included in results 
analysis. Follow up at 8 weeks after cessation of oral 
magnesium was achieved in nineteen subjects. There were no 
complaints of excessive bowel frequency or any other 
significant symptoms in association with magnesium 
supplementation. Appendix 7 contains details of the 
participants, medical conditions and treatment regimens at 
entry.
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a) Biochemical measurements
The results of biochemical measurements are summarised in 
Table 27. Serum magnesium rose significantly as a 
consequence of oral supplementation and the level at 8 
weeks follow up was still significantly higher than the 
baseline level at entry. One subject showed no change in 
serum magnesium following administration of oral 
supplements, the level being static at 0.66 mmol/1. 
Twenty-four hour urine magnesium excretion for this subject 
pre supplementation was 3.5 mmol rising to 5.2 mmol at the 
end of supplementation; this suggests a degree of renal 
magnesium wasting rather than poor compliance with 
supplements or poor gastrointestinal absorption.
Urine magnesium excretion rose in association with oral 
supplements in 8 subjects and was unchanged in one subject. 
Mean value for all 9 subjects rose from 1.37 (sd 1.05) to 
2.82 (sd 1.64) mmol/day (P < 0.01).
There was a significant rise in serum potassium following 
magnesium treatment, compared with placebo. Other 
biochemical comparisons of secondary interest did not reach 
statistical significance at the 5% level following 
Bonferroni correction. However, the five subjects with 
NIDDM or glucose intolerance appeared to have a larger 
average reduction in fasting glucose level than other 
subjects in association with magnesium treatment, changes 
being 0.76 mmol/1 and 0.26 mmol/1 respectively. 
Unfortunately much of the PTH data were rendered invalid by 
accidental premature thawing of samples.
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TABLE 27 Effects of oral magnesium treatment on biochemical 
indices in elderly subjects with persistent mild hypomaqnesaemia
1 2  3 4
Measurement Start Post placebo Post magnesium Follow up
(lab. ref. range)
Serum Mg 0.64 (0.05) 0.65 (0.05) 0.80 (0.08) 0.71 (0.06)
(0.7-1.0 mmol/1) P < 0. 001 P < 0.001
Erythrocyte 2.17 (0.21) 2.19 (0.23) 2.36 (0.38) 2.23 (0.41)
magnesium
(1.75-3.25 mmol/1)
Serum K 4.1 (0.45) 4.2 (0.36) 4.5 (0.47) 4.3 (0.37)
(3.5-5.0 mmol/1) P = 0.02
Serum Ca 2.46 (0.11) 2.41 (0.13) 2.46 (0.09) 2.50 (0.01)
(corrected)
(2.2-2.6 mmol/1)
P. glucose* 5.9 (2.09) 6.4 (2.99) 5.5 (1.84) 5.7 (2.18)
(4.0-5.5 mmol/1)
% glycated 7.4 (1.61) 7.6 (1.77) 7.1 (1.39) 6.9 (0.90)
haemoglobin*
(5.5-8.4)
Total 4.95 (1.34) 5.14 (1.00) 5.09 (1.28) 5.21 (1.59)
cholesterol*
(< 6.5 mmol/1)
HDL 1.17 (0.47) 1.18 (0.37) 1.52 (0.48) 1.43 (0.51)
cholesterol*
(>1.0 mmol/1)
Triglcerides 1.33 (0.60) 1.54 (0.52) 1.35 (0.74) 1.29 (0.68)
( < 2.3 mmol/1)*
Parathyroid 5.4 (3.63) ** 3.6 (2.17) **
hormone*
(1.0-5.0 pmol/1)
All values are quoted as mean (sd).
* = data incomplete (paired data in 19 subjects for glucose and
lipids, in 18 subjects for glycated haemoglobin and in 15 
subjects for parathyroid hormone).
* * = less than 8 samples available for comparison
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b) Other measurements
Blood pressure recordings were quite variable. There were 
slight reductions in blood pressure following placebo and 
again following magnesium but changes were not significant 
(Table 28). Furthermore there was no detectable difference 
in magnesium effects on blood pressure in comparing 
hypertensive subjects (supine BP >160/90 mitiHg) and 
normotensive subjects.
Hand grip strength was unchanged before and after magnesium 
supplementation with mean values of 17 (sd 5.9) and 17 (sd 
6.2) kg force respectively. These are normal values for 
such an elderly population sample (manufacturer's data).
There were 7 subjects in atrial fibrillation before and 
after magnesium treatment in whom PR and QTc intervals 
could not be measured and, despite using ECG recording 
speeds of SOmm/second, accurate measurement of PR and QTc 
intervals in the remaining subjects was difficult. Both 
intervals were quite variable and there was no significant 
change in either as a result of magnesium treatment. Mean 
baseline measurements for PR and QTc respectively of 0.13 
(sd 0.04) and 0.43 (sd 0.028) seconds changed to 0.14 (sd 
0.05) and 0.42 (sd 0.037) seconds following magnesium 
treatment.
Scores from the 3 self rating tests measuring wellbeing and 
morale did not change significantly as a result of 
magnesium treatment.
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TABLE 28
Effects of oral magnesium treatment on blood pressure in elderly 
subjects with persistent mild hypomaqnesaemia
Blood pressure 
mmHg
Before magnesium 
mean (sd)
Start Post
placebo
After magnesium 
mean (sd)
Supine systolic 158 (27.9)
Supine diastolic 81 (16.5)
Erect systolic
Erect diastolic
151 (24.5)
1 (14.0)
154 (28.7)
79 (18.0) 
148 (26.4)
80 (12,6)
151 (25.7) 
78 (12.0) 
145 (27.4) 
77 (12.0)
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12.8. Discussion
a) Biochemical measurements
Magnesium deficiency in illness has been associated with 
abnormalities of other electrolytes including 
hyponatraemia, hypokalaemia, hypocalcaemia and 
hypophosphataemia [86]. In the circumstances described it 
is unlikely that all of these abnormalities were due to 
magnesium deficit but, more likely, most shared a common 
aetiology with magnesium depletion. However, clinical 
problems due to hypokalaemia and hypocalcaemia can arise as 
a result of secondary disturbances in homeostatic 
mechanisms caused by primary magnesium deficit [22], and 
this close relationship of magnesium metabolism with that 
of other electrolytes often makes it difficult to ascribe 
signs and symptoms solely to magnesium deficiency [225].
(1) Magnesium and potassium
Magnesium modulates many of the major potassium transport 
systems and refractory potassium depletion associated with 
magnesium deficiency is a recognised phenomenon. Potassium 
loss in magnesium deficiency seems to be multifactorial and 
various mechanisms have been postulated including reduced 
Na-K-ATPase density and activity in cell membranes 
[183,204,226].
It is interesting, therefore, that there was a rise in 
serum potassium in association with magnesium 
supplementation in this study even though the mean 
pre-treatment serum potassium level was within the normal
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range and no subject was hypokalaemic at the start. In a 
previous study of oral magnesium treatment versus placebo 
in hypomagnesaemic elderly subjects (70-year-old 
in-patients given 12.5 mmol magnesium chloride daily for 3 
weeks), there was a similar significant rise in serum 
potassium within the normal laboratory range. However in 
that study the rise in potassium occured within 8 days of 
starting oral magnesium and was no longer significant after 
3 weeks of treatment [94].
(2) Other biochemical measurements
Through correction for multiple comparisons there was 
inevitable loss of sensitivity in other biochemical 
measurements. Some of the potential benefits of magnesium 
treatment on these measurements merit discussion.
Magnesium, calcium and PTH
Hypocalcaemia can be a prominent manifestation of magnesium 
deficiency and with magnesium replacement both serum 
calcium and serum magnesium return to normal [22]. However, 
as with serum potassium in this study, mean values for 
serum calcium were normal prior to magnesium treatment, 
leaving little scope for significant change.
Although neuromuscular symptoms of magnesium deficiency 
rarely occur in the absence of hypocalcaemia it is unlikely 
that magnesium defiency leads to net calcium loss. Rather 
it appears that there is impairment of the regulatory 
mechanisms which maintain serum calcium in the normal
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range [32]. Two mechanisms have been suggested for 
magnesium dependent hypocalcaemia and both involve 
parathyroid hormone (PTH). There is evidence of end-organ 
resistance to the action of PTH at kidney tubules and bone 
as well as reduced synthesis and secretion of the hormone 
in magnesium deficiency [227,228,229]. Furthermore, PTH 
enhances magnesium resorption from the kidney and secretion 
of the hormone is stimulated by moderately low serum 
magnesium levels [230,231]. It is not surprising therefore 
that PTH levels can be high, normal or low in 
hypomagnesaemic states depending on the degree and duration 
of magnesium deficiency [232].
The biochemical actions of magnesium, calcium and PTH are 
therefore interdependent. Calcium appears to be more potent 
than magnesium in altering the rate of PTH secretion, 
although serum levels of the hormone change rapidly in 
response to changes in serum magnesium. In magnesium 
deficiency there is a rapid rise in PTH following magnesium 
administration, whereas in magnesium excess the reverse 
occurs [228,233,234].
There is a circadian rhythm of PTH secretion with a broad 
peak between 0200 and 0600 hours and a steep but variable 
decline thereafter. Ideally, PTH samples should be taken 
between 1100 and 1400 hours for reproducible results [235]. 
PTH levels in this study were slightly elevated prior to 
magnesium treatment but fell to within the normal range 
with supplementation. Sampling later in the day between 
1100 and 1400 would probably have given lower values all
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round. The fall in serum PTH following magnesium repletion 
for 8 weeks is not surprising, although it is likely that 
PTH rose to a variable degree in at least some subjects at 
the start of magnesium treatment, especially in more 
severely magnesium deficient subjects. However the 
detection of such changes would have required multiple 
blood sampling techniques which were outwith the scope of 
this study.
Magnesium and glucose metabolism
The frequent co-existence of hypomaqnesaemia and diabetes 
mellitus was clearly demonstrated by Jackson and Meir in 
1968 [84], and several studies have since shown evidence of 
a relationship between hypomaqnesaemia and poor diabetic 
control [125,236,237]. The role of magnesium in diabetes 
has recently been reviewed [238]. Studies suggest that 
insulin secretion and sensitivity in elderly subjects with 
non-insulin dependent diabetes mellitus can be improved by 
chronic magnesium supplementation [113,239]. However the 
doses of magnesium given in these studies (120mmol per day 
for 3 weeks) were greatly in excess of the recommended 
dietary requirement and, furthermore, the subjects had 
serum magnesium levels within the normal range prior to 
magnesium administration. It is possible therefore, that 
the beneficial effects observed were due at least in part 
to a pharmacological rather than a physiological effect of 
magnesium.
However, results from this study tend to support the view 
that magnesium treatment, if taken for long enough at
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normal dietary levels, could improve glycaemic status in 
magnesium deficient subjects with glucose intolerance. 
Although the improvements in blood glucose and glycated 
haemoglobin did not reach statistical significance within 
the limits of the study, favourable changes were more 
apparent in subjects with glucose intolerance. Since 
glycated haemoglobin changes more gradually, it would be 
interesting to study the effect of low dose oral magnesium 
treatment in such subjects over a longer period.
Magnesium and blood lipids
Both magnesium deficiency and supplementation have been 
shown to produce changes in blood lipid profile. Magnesium 
may induce a decrease in lipolysis and/or an increase in 
lipoprotein lipase activity leading to an increase in high 
density lipoprotein (HDL) cholesterol and a reduction in 
low density lipoprotein (LDL) cholesterol and triglyceride. 
In contrast, magnesium deficiency enhances catecholamine 
secretion, which results in an increase in lipolysis, 
leading in turn to an increase in very low density 
lipoprotein (VLDL) cholesterol and triglyceride 
[240,241,242,243].
However the evidence of the effects of magnesium therapy on 
lipid profile is conflicting. One supplementation study 
which showed a beneficial effect was not placebo controlled 
[240], whilst in another dietary change probably influenced 
the outcome (the intervention diet, as well as having more 
magnesium, had higher fibre and lower cholesterol content 
than the control diet) [244].
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Two studies which failed to show an effect were performed 
on middle-aged individuals who had normal serum magnesium 
levels and thus had had reduced scope for beneficial change 
[245,246]. A recent double-blind placebo controlled study 
in older subjects, mean age 60 years, with ischaemic heart 
disease but normal serum magnesium levels demonstrated a 
small significant rise in HDL cholesterol and a lowering of 
VLDL cholesterol and triglyceride with magnesium therapy 
[247]. Finally a crossover study comparing the effects of 
magnesium therapy and a bulk laxative on lipids in elderly 
patients, mean age 81 years, detected a slight increase in 
HDL cholesterol and slight lowering of triglyceride values, 
but the magnesium status of the patients was not stated 
though many had been receiving long-term magnesium 
treatment prior to the study [248].
The failure to detect a significant change in the lipid 
profile of elderly hypomagnesaemic subjects in this study 
may be due to inadequate duration of magnesium treatment.
b) Other measurements
Magnesium and electrocardiographic changes
Magnesium depletion may predispose to cardiac arrhythmias 
especially in digitalised patients and atrial fibrillation 
may be refractory to digitalis therapy in hypomagnesaemia 
[46,189,249]. Magnesium therapy has been used to treat and 
prevent ventricular arrhythmias [49,250,251] but serum 
magnesium has often been normal in such reports and the 
abolition of arrhythmias may have been due to a
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non-specific pharmacologic effect rather than due to 
correction of magnesium depletion [48,252]. 
Electrocardiographic changes associated with magnesium 
depletion include prolongation of the PR, QRS and QTc 
intervals as well as ST segment depression but, in most 
clinical circumstances, the relative effects of magnesium 
are difficult to separate from those of calcium and 
potassium [224,253]. Two controlled studies which have 
examined the effect of oral magnesium therapy on the length 
of the QTc interval in digitalised patients produced 
conflicting results.
Lewis et al [254] documented a rise in serum magnesium and 
serum potassium and a reduction in ventricular ectopy with 
magnesium treatment, but there was no significant change in 
QTc interval. However the patients studied had relatively 
normal serum magnesium levels prior to supplementation. In 
contrast, Krasner et al [255] observed a significant 
shortening of the QTc interval following a few days 
treatment with oral magnesium, but serum levels of 
magnesium and potassium were not reported at any stage. 
Furthermore, neither study reported on serum calcium status 
although changes in this could have been important.
The lack of ECG changes in association with magnesium 
supplementation in this study may reflect normal serum 
levels of potassium and calcium in the subjects studied.
Magnesium and blood pressure
Extensive studies on experimental animals have shown that
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magnesium exerts a regulatory role on vascular tone and 
vascular reactivity and that disturbances of magnesium 
metabolism may have profound effects on blood pressure 
[256,257], A clinical study of 73 randomly selected 
subjects, not receiving diuretics, showed an inverse 
correlation between serum magnesium and blood pressure 
[93]. The evidence for magnesium having a blood pressure 
lowering effect in hypertension in clinical practice is 
mixed. Two open studies of oral magnesium supplementation 
in subjects receiving long term diuretic treatment for 
hypertension showed a significant reduction in blood 
pressure following magnesium. One study gave magneium 
aspartate HCL, 15 mmol daily, for 6 months [258] while the 
other gave magnesium oxide, 15 mmol daily, for only 4 weeks 
[155].
However two double blind placebo controlled studies have 
failed to show a significant blood pressure lowering effect 
with magnesium supplementation. One study gave magnesium 
aspartate HCL, 15 mmol daily, for 4 weeks to untreated 
hypertensive subjects [154] and the other gave magnesium 
oxide, 12 mmol daily, for 6 months to hypertensive subjects 
receiving long term diuretics [259].
Subjects who received oral magnesium in the above 4 studies 
had normal serum magnesium levels prior to supplementation 
and in one study the pre-treatment level was rather high at 
0.86mmol/l [154]. It could be argued that there was little 
scope for benefit from low dose oral magnesium therapy in 
such subjects. In this current study subjects were clearly
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hypomagnesaemic before receiving magnesium and yet there 
was no significant fall in blood pressure even though mean 
serum magnesium level rose to near normal with treatment. 
However there was a wide range of blood pressure within the 
study group, many subjects being normotensive, and 
magnesium repletion was probably incomplete in most at the 
end of the treatment phase.
It seems likely that magnesium treatment can have a 
marginal blood pressure lowering effect in hypertension, 
the degree depending on a variety of factors including 
magnesium status, the form and duration of magnesium 
treatment, other electrolytes and therapy, and the degree 
as well as the underlying cause of hypertension. The 
pharmacological and physiological effects of magnesium in 
hypertension need to be more clearly distinguished. A 
study of higher dose magnesium treatment in hypertensive 
subjects would be interesting if a preparation suitable for 
oral administration could be found.
Magnesium in neuromuscular and psychiatric disturbance
Experimental studies in animals and in human volunteers 
have shown that magnesium depletion causes a variety of 
neuromuscular abnormalities which include tremor, 
irritability, muscle weakness and tetany, all of which 
resolve following repletion of magnesium [22,32]. However 
in the various clinical cases which have been reported 
magnesium deficiency has been severe, and symptoms have 
almost always been associated with coexistent abnormalities 
of other electrolytes [224,260,261,262,263].
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The effect of mild isolated hypomagnesaemia on muscle 
strength has not previously been evaluated in clinical 
practice. Hand grip strength has been used to study the 
relationship between potassium and muscle strength in 
elderly subjects. An initial study found a positive 
correlation between dietary potassium intake and grip 
strength [264], but subsequent studies did not find any 
relationship between serum or erythrocyte potassium and 
grip strength and potassium supplementation made no 
difference [265,266]. The lack of effect of magnesium 
supplementation on hand grip strength in this study is in 
keeping with the findings for potassium and would support 
the view that clinically significant muscle weaknes only 
occurs when magnesium depletion is severe and associated 
with abnormal serum calcium [225].
Mood disturbance with symptoms of apathy and depression has 
been reported in association with hypomagnesaemia 
[1,267,268]. In one study depression improved with 
magnesium treatment [189], but affected individuals were 
also suffering from physical illnesses such as heart 
failure and digitalis toxicity and improved mood coincided 
with physical recovery. Furthermore the method of mood 
assessment was not described. A more recent report provides 
good documentation of a case of depression associated with 
severe magnesium depletion. The patient responded to 
correction of magnesium status but serum potassium was also 
low and, once again, mood improvement coincided with 
physical improvement (cessation of severe diarrhoea 
following introduction of a low fat diet) [269].
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In this present study treatment of mild isolated 
hypomagnesaemia did not have any apparent effect on mood 
although none of the subjects were clinically depressed. It 
would therefore seem that mild isolated hypomagnesaemia is 
unlikely to cause significant mood disturbance, and even in 
severe magnesium depletion it may be inappropriate to 
attribute depressive symptoms solely to the magnesium 
deficit.
c) Degree of depletion and adequacy of treatment
In the present study, as well as reduced sensitivity 
through correction for multiple comparisons, inadequate 
correction of magnesium deficit could explain the relative 
lack of change in most measurements in response to oral 
magnesium. The mean 24 hour urine magnesium excretion rose 
following supplementation but the level of excretion was 
still lower than would be expected in younger subjects in 
normal magnesium balance (3.5 - 6.0 mmol/day)
[154,155,156]. Even allowing for the effects of ageing on 
renal magnesium handling, the relatively low urine 
magnesium excretion at the end of the supplementation phase 
suggests incomplete repletion in some subjects.
On the other hand whilst values of magnesium in serum and 
urine support a degree of magnesium depletion prior to 
supplementation, most of the other biochemical indices 
which might theoretically have been affected by magnesium 
depletion were normal or near normal. This would suggest 
that overall cellular magnesium deficiency,if present, was 
mild, an argument supported by the normal erythrocyte
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magnesium level before supplementation. In this context 
the lack of change in most of the other biochemical indices 
is perhaps not surprising. However it is also possible 
that some other significant biochemical changes did occur 
and would have been detected by more frequent sampling, 
especially early in the treatment schedule [94].
At the time of commencing the study there were no 
absorption studies comparing the various magnesium salts 
(oxide, hydroxide, carbonate, chloride, acetate, citrate 
and sulphate), and none had proved to be superior to others 
in treatment of magnesium deficiency by oral repletion 
[216,217,218]. There is now some evidence that magnesium 
citrate is better absorbed in normal healthy individuals 
[270], although the evidence is conflicting [156]. However 
in non-gastrointestinal causes of magnesium deficiency 
absorption of all magnesium salts is likely to be improved 
sufficient for replacement [215,271]. Acidic conditions 
improve solubility of magnesium salts and they should 
therefore be administered with meals [272].
12.9. Summary and conclusion
Apart from a favourable influence on serum potassium, 
administration of oral magnesium treatment to these 
relatively well elderly subjects with mild hypomagnesaemia 
appeared to be of little short term benefit. It is possible 
that cellular magnesium depletion, where it existed, was 
mild and/or magnesium repletion was incomplete. Further 
studies should focus on assessing the effects of
page 189
correcting magnesium deficit in certain single disease 
pathologies such as diabetes mellitus.
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PART 5
CHAPTER 13
REVIEW OF STUDIES AND COMMENTS ON RECENT DEVELOPMENTS
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REVIEW OF STUDIES AND COMMENTS ON FUTURE DEVELOPMENTS
13.1. Introduction
Twelve years have elapsed since I first developed a 
particular interest in the contribution of magnesium 
deficiency to illness in elderly patients and, during the 
intervening period as I have carried out my own 
investigations, I have become deeply impressed by the 
sustained efforts and dedication of other more eminent 
researchers in this field. The questions arising from 
clinical practice which I have sought to answer with regard 
to elderly patients have also been addressed in varying 
detail by numerous other investigators who have usually 
been concerned with problems affecting younger patients. As 
well as clinical studies during this time there has been 
extensive laboratory research which, with the aid of new 
technologies, has resulted in a much greater understanding 
of the actions of magnesium at molecular and cellular 
level. One consequence has been the developing interest in 
possible therapeutic uses for magnesium, most notably in 
cardoivascular disease. Yet, despite this growth in 
knowledge, much remains uncertain about the role of 
magnesium in disease and especially in illnesses affecting 
older people.
13.2. Progress on answers to my original questions
Some of my original questions can be answered. Despite 
dietary magnesium intake in the elderly tending to be lower
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than recommended (see Chapter 3), there is generally a 
slight rise in serum magnesium with age probably reflecting 
the decline in renal function with ageing (see Chapter 4). 
Nevertheless, the average serum level in old age is usually 
very close to that in younger adults. Mean values in 
illness usually coincide with those of the healthy 
population whereas ranges tend to be wider. The mean serum 
magnesium level in the Glasgow population is 0.79 mmol/1 
and approximately 5% of ill elderly patients admitted to 
hospital have a level less than 0.66 mmol/1 (see Chapter
11). A serum level below 0.50 mmol/1 is found in 0.05% of 
elderly hospital patients and is usually associated with 
severe illness. Diuretic drugs, diabetes mellitus and 
excessive alcohol intake are factors which commonly feature 
in milder cases of hypomagnesaemia (see Chapters 10 and 
11).
However the there is still great uncertainty as to the 
significance of hypomagnesaemia in illness. In my 
experience it has been difficult to find clear evidence of 
extra morbidity in elderly patients with hypomagnesaemia 
when compared with those with normal serum magnesium levels 
(see Chapter 11). Mild chronic hypomagnesaemia seems to be 
well tolerated in many elderly subjects and restoration of 
the serum level to normal does not appear to confer any 
great clinical benefit in the short term (see Chapter 12).
Although serum magnesium is the most easily obtained and 
commonly used measure of magnesium status in clinical 
practice, it represents less than 1% of the body content 
and its lack of reliability as a guide to magnesium status
page 193
in illness has been recognised for a long time. Much 
investigative effort has therefore focused on developing 
other more reliable and clinically applicable methods for 
estimation of body magnesium content in order that the 
relative contribution of magnesium deficiency to the 
pathogenesis of various diseases can be more easily 
quantified. Measurement of magnesium in blood cells and 
urine and development of protocols for parenteral magnesium 
load/retention studies have all received much attention in 
recent years. Each technique in turn tends to have been 
heralded as the answer to assessment of magnesium status 
but, with the passage of time, the limitations of each have 
become apparent. Like serum measurements, cellular 
magnesium measurements can act as a guide to the magnesium 
status of a healthy population but biological variability 
and analytical imprecision greatly limit their use in a 
single individual. Furthermore, it is often uncertain to 
what extent changes in cell magnesium during illness 
reflect altered body magnesium content as oppose to mere 
alterations in the characteristics of the cells themselves 
(see Chapters 5 and 6). The decline in renal function with 
age and the difficulty with accurate urine collection pose 
problems in the execution and interpretation of both 
standard urine measurements and parenteral magnesium load 
studies in ill elderly patients (see Chapters 7 and 8).
Autopsy evidence points to a reduction in muscle magnesium 
stores with age (see Chapter 9). Muscle and bone biopsies 
have been used in some clinical studies but these 
procedures are neither acceptable nor practical for routine
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use in ill elderly patients. Furthermore, the significance 
of low muscle values in relation to the readily 
exchangeable magnesium pool during illness is unclear. At 
present, therefore, there is no single laboratory test in 
routine clinical use which unequivocally reveals magnesium 
deficiency.
13.3. Advanced techniques for future use
Most studies to date including my own have measured total 
magnesium in serum, urine, cells and tissues but it is now 
generally accepted that free ionised magnesium (Mg=^) is 
the important component in magnesium-dependent biological 
processes. Free Mg=^ normally comprises 60% of serum 
magnesium and 10 - 20% of cellular magnesium [74,274,275]. 
The equilibrium between free Mg=^ and total magnesium 
varies especially during illness, thus rendering 
measurements of the latter in various body compartments 
less valuable than previously appreciated.
The ability to measure free Mg=^ easily would be a major 
step forward. Technology that would permit the rapid 
accurate determination of Mg=^ flux into and out of cells 
would contribute immensely to our understanding of the 
contribution of magnesium to various clinical deficiency 
syndromes and illness. However accurate measurement of 
free Mg=^ in serum alone requires rigorous analytic 
techniques which are currently beyond the resources of most 
clinicians. Protein-magnesium bonds are extremely labile 
and serum samples must therefore be collected in strictly
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anaerobic conditions to prevent any loss of carbon dioxide 
which would change the pH and the protein-bound fraction. 
Strict temperature control is necessary for the same reason 
[276,277,278]
Measurement of intracellular free Mg=* is even more 
difficult but various advanced laboratory techniques have 
been developed and evaluated in vitro. These include use of 
nuclear magnetic resonance spectroscopy (NMR) 
[275,279,280,281], Mg=^ selective microelectrodes 
[282], zero point titration techniques (ZPT) [281,283,284] 
and fluorescent dyes [285,286,287].
Each of these methods has limitations but thus far ZPT and 
NMR have shown promise for future clinical use [281]. One 
NMR study has revealed a relationship between low 
intracellular Mg=^, raised Ca=^ and the degree of blood 
pressure elevation in hypertensive subjects [288]. More 
recently, again from NMR studies, there is evidence of 
reduced intracellular Mg=^ in non-insulin dependent 
diabetes mellitus with the possibility that magnesium 
deficiency may be a key factor leading to enhanced platelet 
reactivity in affected subjects [289,290].
Such information supports existing evidence linking 
magnesium deficiency to cardiovascular disease and diabetes 
mellitus and has led to the hypothesis that both diseases 
have a common ionic basis in intracellular magnesium 
deficiency [291].
However, at present the cell separation technology
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available to most clinicians for measurement of total 
magnesium in cells is unreliable. Therefore, for the 
forseeable future, it is difficult to envisage measurement 
of intracellular free Mg=^ in routine clinical practice, 
since the problems of cell separation would have to be 
overcome without disturbing the ionic equilibrium within 
the cell.
13.4. Concluding remarks
Like many more eminent researchers I have found that the 
search for answers to apparently simple questions about 
magnesium in clinical practice has produced few 
satisfactory solutions, but rather has resulted in a series 
of more complicated enquiries. This enigmatic element still 
holds many secrets and for the time being clinicians like 
myself must continue rely on clinical experience and simple 
laboratory measurements to judge the contribution of 
magnesium deficiency to illness in the individual patient.
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APPENDIX 1
Magnesium content of various foods
Food Magnesium/Portion weight 
(mmol/kg)
Porridge (made with water)
All Bran 
Weetabix (2)
Wheat Bran 
Soya Flour 
Wholemeal Bread 
Rye Crispbread 
Oatcakes
Sardines (excluding oil)
Prawn, boiled 
Nuts e.g. peanuts 
Apricots (fresh, raw)
Bananas (without skin)
Figs
Dried fruits e.g. sultanas 
Sweetcorn
Pulses e.g. tinned peas
Potatoes, boiled
Potato crisps (1 small packet)
Cabbage, boiled
Carrots, boiled
Spinach, boiled
Whole milk
Instant coffee (powder or granules)
Cocoa powder
Black Treacle
Peanut Butter
Chocolate, plain
7.4
86.4
49.4 
214
98.8 
31.3 
41 
41 
21
17 
86
18 
14 
30 
12
9 
8 
5 
19 
1 
2
14.0 
4.5
160
214
57.6
74.1
41.2
Adapted from McCance and Widdowson: The composition of 
foods, 5th Ed. London: HMSO 1991 [52].
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APPENDIX 2
Characteristics of aged autopsy subjects (Chapter 9)
Sex Age Duration of 
illness
Diseases contributing to death
1 m 73 chronic PVD, CVI, pneumonia
2 m 84 chronic Pneumonia, COAD
3 m 72 chronic Pneumonia, IHD, cirrhosis
4 m 86 chronic Pneumonia,IHD, pulmonary fibrosis
5 f 72 chronic CVD, IHD
6 f 73 chronic Bladder carcinoma, peritonitis
7 f 85 short PTE, IHD, CRF
8 f 91 chronic IHD, pneumonia
9 f 85 chronic PVD, bacterial meningitis
10 m 73 chronic Bronchial carcinoma
11 m 82 chronic IHD, pneumonia, peptic ulceration
12 m 69 sudden IHD, MI
13 f 82 short CVI, MI, IHD
14 f 84 chronic IHD, CCF, chronic pancreatitis
15 f 83 chronic Bowel infarction, CRF, CVD
16 f 77 chronic IHD, CCF, pneumonia
17 m 88 chronic Emphysema, CRF
18 m 80 chronic IHD,pneumonia,Parkinson's disease
19 f 84 chronic Bronchial carcinoma
20 m 71 sudden Peritonitis
21 m 73 chronic Prostatic carcinoma, CRF
22 f 85 sudden MI, IHD
23 f 88 chronic IHD, CCF, ruptured gall bladder
24 m 84 short Pneumonia
25 m 77 chronic CVD, carcinoma of caecum
26 f 84 short CVI, IHD, CRF
27 f 94 sudden Pneumonia,cholecystitis,diabetes
28 m 85 chronic IHD, CCF, mitral valve disease
29 f 84 chronic IHD, PVD, PTE
30 f 83 chronic Emphysema
31 f 76 sudden CVI, pneumonia
32 m 72 chronic Pneumonia, prostatic carcinoma
33 f 76 short MI, IHD, CCF, diabetes
PVD = peripheral vascular disease
CVD = cerebrovascular disease
CRF = chronic renal failure
PTE = pulmonary thromboembolism
CVI = cerebrovascular incident
IHD = ischaemic heart disease
COAD = chronic obstructive airways disease
MI = myocardial infarction
CCF = congestive cardiac failure
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APPENDIX 3
Characteristics and clinical outcome in elderly patients 
with severe hypomagnesaemia on admission to hospital (serum 
magnesium < 0.50 mmol/1)
Sex Age Serum mg 
mmol/1 
(lowest 
value)
Diagnoses and comment 
(duration of illness)
Clinical 
outcome 
at six 
months
68 0.31
67 0.47*
93 0.49*
84 0.44*
F 84 0.48*
* *
F 80 0.38*
F 80 0.48*
F 71 0.48
Dysphagia Survived
Oesophagitis
Diverticulitis
Presented with weight loss
and diarrhoea.
(4 months)
Multiple fractures Survived
(road traffic accident)
Epilepsy 
Hypertension 
(2 months)
Metastatic carcinoma Died (PM)
of colon (2 weeks)
Pneumonia Died (PM)
NIDDM
CCF
(12 weeks)
Serum magnesium rose to
0.67 mmol/1 before death
Peripheral vascular disease Survived
CCF
(one week)
CCF Survived
Alcohol excess 
Recurrent hypomagnesaemia 
(2 episodes in 6 months;
2 weeks and 1 week)
CCF Survived
Pneumonia
Recurrent hypomagnesaemia 
(2 episodes in 5 months:
1 week each)
Alcohol excess Survived
Recurrent hypomagnesaemia 
(2 episodes in 5 months:
2 weeks and 1 week)
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APPENDIX 3 continued
Sex Age Serum mg 
mmol/1 
(lowest 
value)
Diagnoses and comment 
(duration of illness)
Clinical 
outcome 
at six 
months
70 0.42 Septicaemia (Staph aureus) 
Profuse diarrhoea 
(1 week)
Survived
76 0.22*
M
M
96
66
70
71
80
0.45*
* *
77 0.48
0.45
0.44
0.49*
0.48
M 73 0.41
75 0.42
F 79 0.27*
CCF Survived
Jaundice
Gall stones
Henoch-Schonlein purpura 
(2 months)
CCF Survived
(one week)
Iatrogenic hypercalcaemia Survived
(calcium supplements 
post thyroidectomy: 
serum calcium 3.70 mmol/1)
(2 weeks)
Metastatic carcinoma Died
of prostate 
(4 months)
Alcohol excess Survived
(2 weeks)
Pneumonia Died (PM)
Renal artery stenosis 
Hypertension 
(3 days)
Metastatic carcinoma Died (PM)
of bronchus 
Profuse diarrhoea 
(4 days)
Alcohol excess Survived
(1 week)
Rheumatoid arthritis Survived
Ulcerative colitis 
Acute renal failure 
(3 weeks)
CCF Died (PM)
Pulmonary fibrosis 
Biliary obstruction 
(4 days)
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APPENDIX 3 continued
Sex Age Serum mg 
mmol/I 
(lowest 
value)
Diagnoses and comment 
(duration of illness)
Clinical 
outcome 
at six 
months
88 0.42*
88
77
0.49*
* *
0.45
* *
CCF
Chronic renal failure 
Carcinoma of colon 
(recurrent hypomagnesaemia 
until death at 10 months)
Pseudomembranous colitis 
Myocardial infarction 
(4 weeks)
Cerebrovascular disease
Pneumonia
(5 weeks)
Survived
Died
(4 weeks)
Died (PM) 
(5 weeks)
* receiving diuretic treatment
** single serum magnesium sample less than 0.50 mmol/1. (All 
other patients had multiple samples less than 0.50 mmol/1)
Abbreviation key
CCF = congestive cardiac failure
NIDDM = non insulin dependent diabetes mellitus
PM = post-mortem examination performed
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APPENDIX 4 (Chapter 12)
GENERAL HEALTH QUESTIONAIRE
Please read each question carefully. Think about your 
own situation and tick one answer in each case.
H A V E  Y O U  R E C E N T L Y :
1 been able to 
concentrate on
better
than
usual
same as 
usual
less
than
usual
much
less
than
whatever you're doing? usual
2 lost much sleep 
over worry?
not at 
all
no more
than
usual
rather
more
than
usual
much
more
than
usual
3 felt that you were 
playing a useful 
part in things?
more so
than
usual
same as 
usual
less
useful
than
usual
much
less
useful
4 felt capable about 
making decisions 
about things?
more so
than
usual
same as 
usual
less so
than
usual
much
less
than
usual
5 felt constantly 
under strain?
not at 
all
no more
than
usual
rather
more
than
usual
much
more
than
usual
5 felt you couldn't
overcome difficulties?
not at 
all
no more
than
usual
rather
more
than
usual
much
more
than
usual
7 been able to enjoy 
your normal day to 
day activities?
more so
than
usual
same as 
usual
less so
than
usual
much
less
than
usual
8 been able to face 
up to your problems?
more so
than
usual
same as 
usual
less so
than
usual
much
less
able
9 been feeling unhappy 
or depressed?
not at 
all
no more
than
usual
rather
more
than
usual
much
more
than
usual
10 been losing 
confidence in 
yourself?
not at 
all
no more
than
usual
rather
more
than
usual
much
more
than
usual
11 been thinking of 
yourself as a 
worthless person?
not at 
all
no more
than
usual
rather
more
than
usual
much
more
than
usual
12 been feeling quite 
happy, all things 
considered?
more so
than
usual
about the 
same as 
usual
less so.
than
usual
much
less
than
usual
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APPENDIX 5 (Chapter 12)
WAKEFIELD SELF-ASSESSMENT INVENTORY
Read these statements carefully, one at a time, and underline the 
response which best indicates how you are. It is important to 
indicate how you are now, not how you were, or how you would hope 
to be.
1 I feel miserable and sad
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(d) No, not at all
I get off to sleep easily 
without sleeping tablets
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(c) No, not at all
I find it easy to do the 
things I used to
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(d) No, not at all
I feel anxious when I go out 
of the house on my own
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(c) No, not at all
I get frightened or panic 
for no reason at all
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(d) No, not at all
I have lost interest in 
things
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(c) No, not at all
I have weeping spells, 
or I feel like it
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(d) No, not at all
10 I get tired for no reason
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(c) No, not at all
I still enjoy the 
things I used to
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(d) No, not at all
11 I am more irritable than 
usual
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(c) No, not at all
I am restless and can't 
keep still
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(d) No, not at all
12 I wake early and sleep badly 
for the rest of the night
(a) Yes, definitely
(b) Yes, sometimes
(c) No, not much
(c) No, not at all
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APPENDIX 6 (Chapter 12)
THE "FACES" SCALE
B D
1 Which of these faces best represents how you feel right 
now? ..........
2 Which of these faces best represents how you feel most 
of the time? ..........
Insert one letter for each answer
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APPENDIX 7
Characteristics of elderly subjects with mild persistent 
hypomagnesaemia who participated in the study of oral 
magnesium treatment (Chapter 12)
Subject Sex Age
1 80 M
2 93 F
3 86 F
4 82 F
5 81 F
6 73 F
7 72 F
8 95 F
9 76 F
10 82 F
11 89 F
12 73 F
13 76 F
14 86 F
Diagnosis 
CVI, COAD
CVI, CF, AF
CF, AF 
CF, AF
Hypertension
Osteomalacia, 
malabsorption
OA, PU
CF, AF
Hypertension 
NIDDM (diet)
CF,
CHO intolerance 
CF
OA, gastritis
Hypertension 
NIDDM (diet)
Hypothyroidism,
hypertension
Treatment
Salbutamol (SR),
aspirin
carbamezapine
Digoxin, temazepam 
bendrofluazide, 
lactulose
Digoxin, 
bendrofluazide
Digoxin, bumetanide
Bendrofluazide
l-alpha,OH,vit D 
ibuprofen
Cimetidine,
paracetamol
Digoxin, 
bendroflazide
Bendrofluazide, 
nifedipine
Frusemide + 
potassium
Frusemide + 
amiloride
Piroxicam,
misoprostol
Bendrofluazide, 
nifedipine
Thyroxine, 
bendrofluazide
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APPENDIX 7 continued
Characteristics of elderly subjects with mild persistent 
hypomagnesaemia who participated in the study of oral 
magnesium treatment (Chapter 12)
Subject Sex Age Diagnosis Treatment
15
16
17
18
19
20
21
22
75
78
70
78
81
82
80 M
86
M
F
CVI
RA, PU
Aspirin
Ibuprofen,
misoprostol
Crohn's disease Frusemide, digoxin.
CF
CF
CVI
CF, AF 
CF, AF
nifedipine,
prednisolone
Bumetanide + 
potassium
Aspirin
Frusemide, digoxin 
potassium.
Hydrochlorothiazide
CHO intolerance amiloride, digoxin
CF, AF, OA Digoxin, ibuprofen
CHO intolerance bendrofluazide.
Appendix 7 diagnostic key
CF = cardiac failure
CVI = cerebrovascular incident
AF = atrial fibrillation
PU = peptic ulceration
OA = osteoarthritis
RA = rheumatoid arthritis
NIDDM = non-insulin dependent diabetes mellitus 
CHO = carbohydrate
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